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Abbreviation List 
 
ADCC – antibody-dependent cell-mediated cytotoxicity
AM – alveolar macrophage 
APC – antigen-presenting cell 
ASC – apoptosis-associated speck-like protein 
ASL – airway surface liquid 
C1QBP – component 1 binding protein  
CARD – caspase activation and recruitment domain 
CD32 – cell surface receptor 
CD55 – gene, decay-accelerating factor 55 
CMAS – gene, cystidine monophosphate N-acetylneuraminic acid synthase
CMP – cystidine monophosphate
CRD – carbohydrate recognizing domain 
CTD – C-terminal domain 
CTL – cytotoxic T lymphocyte  
DC – dendritic cell 
DDX58 – gene, encodes RIG-I 
DHX58 – gene, encodes LGP2 
DNAJC3 – gene, encodes P58IPK
EIF2AK2 – gene, encoded PKR 
ER – endoplasmic reticulum 
HLA – human leukocyte antigen; human version of the major histocomatibility complex (MHC) 
IAV – influenza-A virus 
IFIT – interferon-induced proteins with tetratricopeptide
IFN – interferon 
IgA – immunoglobulin A 
IgG – Immunoglobulin G 
IgM – immunoglobulin M 
LGP2 – laboratory of genetics and physiology 2 protein
LRR – leucine-rich-repeat 
MAVS – mitochondrial antiviral-signaling protein 
MUC – gene, mucin  
NBD – nucleotide-binding domain
Neu5Ac – sialic acid (also known as neuraminic acid or N-acetylneuraminic acid)
NK – natural killer cell 
NLR – NOD-like receptor 
NOS2 – nitric oxide synthase 2 
NP – influenza virus nucleoprotein
PAMP – pathogen-associated molecular pattern 
PKR – ssRNA-binding protein kinase 
PRR – pattern recognition receptor
PYD – pyrin domain 
RIG-I – retinoic acid-inducible gene I product 
RLR – RIG-I-like receptor 
RPAIN – replication protein A interacting protein 
SLC35A2 – gene, solute carrier family 35 type A2 
ST3GAL – gene, sialyltransferase that binds sialic acid to a 2,3 positioned galactose
ST6GAL – gene, sialyltransferase that binds sialic acid to a 2,6 positioned galactose
TAP – transporter of antigen processing 
TCR – T-cell receptor 
TLR – toll-like receptor 
TNF – tumor necrosis factor 
TRIM25 – tripartite-motif-containing protein 25 
VISA – gene, encodes MAVS 
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Abstract 
The aftermath of influenza infection is determined by a complex set of host-pathogen interactions, 
where genomic variability on both viral and host sides influences the final outcome. Although there 
exists large body of literature describing influenza virus variability, only a very small fraction covers 
the issue of host variance. The goal of this review is to explore the variability of host genes 
responsible for host-pathogen interactions, paying particular attention to genes responsible for the 
presence of sialylated glycans in the host endothelial membrane, mucus, genes used by viral immune 
escape mechanisms, and genes particularly expressed after vaccination, since they are more likely to 
have a direct influence on the infection outcome. 
 
Introduction 
Influenza virus is one of the most important cause of infections of the respiratory tract, with 3–5 
million clinical infections and 250,000–500,000 fatal cases annually (Dawood et al., 2012; Simonsen 
et al., 2013; WHO, 2014). Immunity to influenza virus infection has been a research topic for more 
than 70 years (Andrewes, 1939) due to the relevant impact the illness has on global health care. 
Although some aspects of the immunological response to influenza-Are well understood, there are still 
many open research questions in this field.  
The influence of viral genetic variability on infection is undoubtedly the most important and heavily 
investigated topic (Hatta et al., 2001; Wagner et al., 2002; Uipraserktul et al., 2005; Gambaryan et al., 
2006; Bateman et al., 2008; Nicholls et al., 2008; Das et al., 2010; Jayamaran et al., 2012; 
Sriwilaijaroen & Suzuki, 2012; Thakaramaran et al., 2012; Guarnaccia et al., 2013; Koel et al., 2013; 
Sun et al., 2013; Thakaramaran et al., 2013; El Moussi et al., 2014; Qi et al. 2014; Su et al., 2014). 
The high antigenic drift rate observed in the influenza virus is one of primary reasons why constantly 
updated seasonal influenza vaccination is recommended. Genomic variability of the influenza virus 
has been largely investigated over the years, yet the variability of the host remains a sparsely 
documented topic, despite its crucial impact on the immune response (Wijburg et al., 1997; 
Matrosovich & Klenk, 2003; Schmitz et al., 2005; Jayasekera et al., 2007; Koyama et al., 2007; 
Throsby et al. 2008; Ichinohe et al., 2009; Sabbah et al., 2009; Kreijtz et al., 2011; Zhou et al., 2012; 
Henn et al., 2013; Hertz et al., 2013; Lin & Brass, 2013) and the course of infection. The goal of this 
review is to explore genomic variability in the host genes that mediate host-pathogen interactions. 
Implemented genomic approach focuses on the major gene variants found in the 1000 Genomes 
Project data (the 1000 Genomes Project Consortium, 2010; Clarke et al., 2012), and is aimed at 
understanding how much variability is present across different human populations, and at identifying 
conservation level of such genes. We attempted to predict whether the genetic variants found in large 
human populations affect the specificity of virus binding and subsequent effectiveness of the immune 
response. Genes related to virus entry into the host cell are responsible for the production and 
assembly of Neu5Ac-α2,6-Galβ1,4-GlcNAc (human), and the Neu5ac-α2,3-Galβ1,4-GlcNAc (avian) 
receptors in the host membrane. Both the human and avian influenza-A virus receptor proteins, 
hemagglutinin (HA) and neuraminidase (NA), interact with the above glycans at the beginning of 
infection. Sialic acid composition and modifications of amino acids near the binding site for HA, and 
the subsequent site of interaction with NA, influence the success of infection. 
Virus binding to cell  
The human influenza virus attaches to the host cell by binding to Neu5Ac-α2,6-Gal-β1,4-GlcNAc 
(2,6-linked, in short), a sialic acid modification to glycans that is extremely abundant in humans, 
especially in the epithelial cells of the upper respiratory tract (Skehel & Wiley, 2000). The mucin that 
protects the cells in the human upper respiratory tract is equally enriched with Neu5Ac-α2,3-Gal (2,3-
linked; Cohen et al., 2013), which is recognized by avian strains of influenza virus (Cone, 2009). Both 
types of sialylglycans are present in different proportions at different regions of the human respiratory 
tract, and are essential for a success of the infection by influenza-A (Shynia et al., 2006; Nicholls et 
al., 2007). 
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Sialyltransferases are responsible for adding Neu5Ac moiety to the glycans (Cohen & Varki, 2010). 
Twenty genes coding for sialyltransferase were described in the human genome (Harduin-Lepers et 
al., 2005). Both α2,3 sialyltransferases (ST3GAL1 to 6) and α2,6 sialyltransferases (ST6GAL1 and 2) 
are responsible for the sialylation of glycans in the human cell membrane. Some of these genes are 
expressed only in specific tissues, and different sialyltransferases bind the Neu5Ac to different 
substrates. For example, ST6GAL1 adds the sialic acid moiety in the α2,6 position to the type-II 
glycans (Galβ1,4GlcNAc) that are N-linked, and sometimes to O-linked glycoproteins as well. In 
contrast, ST6GAL2, which is expressed only in brain and fetal tissues, adds the sialic acid in the α2,6 
position to oligossaccharides, but not to proteins (Glaser et al., 2007). Therefore, we selected 
ST6GAL1, ST3GAL1, ST3GAL2, ST3GAL4 and ST3GAL5 genes as relevant for this review, since 
those are expressed in the human respiratory tract (Kitagawa & Paulson, 1994; Harduin-Lepers et al., 
2001; Glaser et al., 2007). 
 
 
 
Figure 1  Influenza virus life cycle 
 
During the first step of influenza virus infection, the viral glycoprotein HA binds to the receptors on the host cell 
surface. The virus is then internalized via endocytosis. The low endosomal pH triggers a conformational change in the 
HA, leading to the fusion of the virus with endosomes and the consequent release of viral ribonucleoprotein complexes 
(vRNPs) in the cytoplasm. The vRNPs are transported into the nucleus, where both mRNA transcription and vRNA 
replication/new vRNPs assembly occurs. Translation of viral mRNAs takes place differently in both cytoplasm and 
endoplasmic reticulum (ER). Following the post-translational modifications (PTM) of certain viral proteins, the 
structural components of the viral particle are transported to the plasma membrane along with new vRNPs, where viral 
assembly and virus budding take place. 
 
In order to analyze mechanisms and mutations that can confer complete cell immunity to influenza 
viruses, the insertional mutagenesis assays were developed in a human cell line (haploid for all 
chromosomes except chromosome 8). They showed that three independent insertions in the SLC35A2 
gene, and two in the CMAS gene are associated with complete cell immunity to influenza viruses 
(Carette et al. 2009). CMAS encodes the enzyme that binds Neu5Ac to a cystidine monophosphate 
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residue. The sialyltransferases cannot transfer Neu5Ac into an acceptor unless it is bound to a CMP 
residue, because free Neu5Ac cannot be transported to the Golgi membrane (Fleischer, 1998; Munster 
et al., 1998). SLC35A2 encodes the solute carrier–family 35 transporter type A2, responsible for 
transporting CMP-Neu5Ac from the cytoplasm to the Golgi membrane.  
The glycan receptors are important in cell signaling and adhesion; therefore, they are important for 
the cell's life cycle. Considering the fundamental role of genes coding for the production of the glycan 
receptor in susceptibility to influenza, we decided to verify whether the lack of expression of these 
genes causes any known human disease. Indeed, a malfunction of the SLC35A2 gene is followed by a 
severe disease: congenital disorder of glycosylation type IIm (Ng et al., 2013). Defects arising from 
deficient SLC35A2 expression are severe and include developmental delays, hypotonia, variable 
ocular anomalies, variable brain malformations associated with an unusual serum transferrin profile, 
seizures, hypsarrhythmia, poor feeding, microcephaly, recurrent infections, dysmorphic features, 
shortened limbs, and coagulation defects (Ng et al., 2013). All subjects showed diminished 
proportions of sialic acid glycoconjugates. The profound phenotype and short life span in these 
patients suggests that malfunctioning of SLC35A2 and/or CMAS is incompatible with life. Therefore, 
the influenza virus binds to an essential host receptor.  
We examined whether variability of the genes responsible for production and assembly of the 
sialylglycan are indeed more changeable, by searching for the variants described for those genes in the 
1000 Genomes ENSEMBL Browser during the pilot phase of the project (1000 Genomes Consortium, 
2010). The genes length ranged from 8.8Kb (SLC35A2) to 148Kb (ST6GAL1), with the latter 
showing 0.5 variants per Kb, whilst the first showed 7.2 variants per Kb. Most of the variants found in 
any of the analyzed genes were mutations in intronic regions (29–66.7% of described variants), except 
for the ST6GAL1 gene, for which 72% of variants were located in the 3’UTR region, with 9% 
variance (c.f. Table 1). 
 
Table 1. List of variants for seven genes involved in virus binding 
Type of variant* CMAS SLC35A2 ST3GAL1 ST3GAL2 ST3GAL4 ST3GAL5 ST6GAL1 Total 
Frameshift coding 0 4 0 2 4 0 0 10 
Non-synonymous coding 3 14 4 2 7 11 0 41 
Splice Site 3 0 4 2 8 5 1 23 
Synonymous coding 1 2 10 2 17 0 9 41 
Intronic 20 30 27 24 67 83 7 258 
5'UTR 1 1 21 17 1 6 2 49 
3'UTR 2 10 12 32 6 82 54 198 
Upstream 1 0 0 1 3 5 0 10 
Downstream 2 2 10 2 1 4 2 23 
Total Number of Variants 33 63 88 84 114 196 75 653 
 
The genetic variants described in the 1000 Genomes Project Pilot data are: Frameshift coding: structural mutation in coding sequence, resulting in a frame shift 
of reading (A, B); Non-synonymous coding: nucleotide substitution in the coding sequence (A, B), resulting in an amino acid change in the peptide chain (A, C); 
Splice Site: 1-3bp into an exon or 3-8bp into an intron (A); Synonymous coding: nucleotide substitution in coding sequence (A, B), but not resulting in an amino 
acid change (C); Intronic: mutation in intron (A); 5'UTR: in 5’ untranslated region (A, B); 3'UTR: in 3’ untranslated region (A, B); Upstream: mutation within 
5kb upstream of the 5' end of transcript (A); Downstream: mutation within 5kb downstream of the 3' end of transcript (A).
 
SLC35A2 showed both non-synonymous and frame-shift coding variants, which could potentially 
alter the phenotype of the resulting protein. Interestingly, SLC35A2 was the only gene examined in 
which malfunction causes a severe and ultimately lethal congenital disorder and the absence of a 
functional copy of the gene causes severe developmental defects (Ng et al., 2013). Nevertheless, 
considering the crucial importance of CMP-Neu5Ac transport from the cytoplasm to Golgi apparatus, 
some studies have shown that SLC35A3 (which is an UDP-Gal/UDP-GlcNAc transporter) can help 
the transporting of CMP-Neu5Ac in cases where SLC35A2 is working poorly (Olczak et al., 2013). 
None of the two insertions in the CMAS gene nor the three insertions in the SLC35A2 gene described 
by Carette et al. (2009) were found in the screening of the 1000 Genomes Project data. 
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Several articles reported a change in binding affinity of the HA molecule to the host receptor that 
are related to amino acid changes in the structure of HA, which cause a conformational change in the 
receptor binding site of the protein (Ohuchi et al., 1997; Matrosovich et al., 2000; Hatta et al., 2001; 
Gambaryan et al., 2006; Bateman et al., 2008; Tria et al., 2013). The binding of influenza-A avian 
virus (IAV) HA to the sialylglycan (α2,3 or α2,6 linked) is rather weak (Kdiss>10-4M). As result, 
successful entry of a virus into a cell is facilitated when several HAs bind to several sialylglycans 
(Matrosovich & Klenk, 2003). If any variant of analyzed  genes affect the availability or the quantity 
of sialylglycans on the cell surface, it will also affect the success rate of cell infection. In this context, 
it is known that the topology and density of glycans in the membrane, as well as time of incubation, 
are also involved in the successful binding of proteins to glycans (Lewallen et al., 2009), and that the 
differences in specificity of binding of avian and human influenza virus rely not only on α2,3-linked or 
α2,6-linked sialic acid binding, but also on differences in the structure of the sialylated glycans. 
Human-like strains of influenza virus bind to glycans that display an open-umbrella shape, which is 
formed by α2,6 sialic acids bound to long chains of oligossaccharides. On the other hand, avian strains 
of influenza virus HA bind to α2,3 or α2,6 sialic acid only if they are bound to short chains of 
oligosaccharides, in a cone shape (Chandraserakan et al., 2008). 
The binding of influenza virus and viral entry into a cell (Fig. 1) are two early steps during the 
virus-host interaction, in which human genetic variability can either predispose or protect from 
infection. How the virus accesses the cell and the numerous host mechanisms preventing virus 
infection are also subject to genetic changes. One host gene that protects against influenza infection is 
CD55, coding for a protective decay-accelerating factor that prevents cell damage caused by 
complement molecules (Osuka et al., 2007). The CD55 gene is expressed in all types of cells in the 
two forms: a GPI-membrane anchored form (mCD55), which is particularly well expressed in the 
plasma membrane of all blood tract cells, and a soluble form (sCD55) found in body fluids (Medof et 
al., 1987). The CD55 is associated with prevention of lung lesions, being largely expressed in this type 
of tissue (Osuka et al., 2007). A SNP (rs2564978) on the promoter region of the CD55 gene was found 
to be associated with severe influenza-A H1N1 pandemic 2009 infection in Chinese and Japanese 
individuals. The rs2564978T/T genotype was found to be highly associated with severe form of 
influenza, while the rs2564978C/C was associated with a less severe form (Zhou et al., 2012). 
When searching the frequency of this SNP in the 1000 Genomes Project database, we found that 
rs2564978T is more frequent in Chinese populations (54% in Chinese from Beijing and 63% in 
Southern Han Chinese), while in other populations its frequency ranged from 1.7% (Yoruba from 
Ibadan) to 39% (Japanese from Tokyo). Despite the higher frequency of the protective alleles in 
Yoruba, the African population was the one that suffered the most from the spread of the 
influenza-A H1N1 2009 pandemic, with a relative death rate of 7.8 deaths per 100,000 habitants 
in the first 12 months of circulation of the virus (Dawood et al., 2012). The second severely 
affected population was the Southern Asians, ranging from 3.3 deaths per 100,000 habitants 
(considering only respiratory failure), to 4.4 deaths per 100,000 habitants (considering both 
respiratory and cardiovascular failures associated with influenza). Europeans and Western Pacific 
individuals showed the smallest rates of deaths per 100,000 habitants (1.8 and 1.7, respectively), 
and indeed those populations have the highest frequencies of the protective C allele (70–90%). 
 
The protective properties of mucus against Influenza-A Viruses 
Epithelial mucus is a dynamic semipermeable barrier that enables exchange of nutrients, water, 
gases, odorants, hormones and gametes while being impermeable to most bacteria and many 
pathogens (Cone, 2009). It is present in the respiratory tract, where it is called Airway Surface Liquid 
(ASL) and constitutes a primary innate barrier to foreign molecules and pathogens (Lillehoj & Kim, 
2002). The ASL consists of a strictly regulated mixture of water, salts and various macromolecules 
such as mucins, proteoglycans, lipids, and other proteins that confer viscosity and defensive function 
to ASL. Whenever one of these components is missing, or is present at suboptimal concentrations, 
there is large probability of disease such as asthma and other respiratory diseases (Lillehoj & Kim, 
2002). ASL is rich in α2,3-linked and α2,6-linked moieties, both in secreted and membrane-bound 
forms (Nicholls et al., 2007). 
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It was suggested that mucins are the most important components of ASL, because of their high 
concentrations in the secreted portion of the mucus and high number of genes encoding both 
membrane-bound and secreted forms of mucins expressed in the human genome. Thirteen mucin-
encoding genes were described in the human genome, eight of which are expressed in the respiratory 
tract – products of the five are secreted, and of the three remaining are membrane-bound (Lillehoj & 
Kim, 2002). Mucins are high-molecular-weight glycoproteins containing variable numbers of amino 
acid tandem repeats enriched in Ser, Thr and Pro residues (Voynow et al., 1998; Ogasawara et al., 
2007). The presence of these repetitive amino acids is responsible for heavy glycosylation and thus 
polydispersity in both size and charge of mucin molecules. Glycosylation takes place between the 
Ser/Thr moieties of the peptide backbone and N-acetylgalactosamine of the oligosaccharides, that is 
characteristic of O-linked glycoproteins (Lillehoj & Kim, 2002; Rose & Voynow, 2006). 95% of all 
secreted mucins are the MUC5 type, which is heavily O-glycosylated (Lillehoj & Kim, 2002) and is 
acceptor of both α2,3-linked and α2,6-linked sialic acids. The sialic acid bound to these mucins is 
responsible for the lubricant and high viscosity features of the mucus (Nicholls et al., 2012, Varki & 
Gagneux, 2012). MUC2 is a secreted form of the protein that comprise 2.5% of mucins in the ASL 
(Kirkham et al., 2002; Rose & Voynow, 2006) containing about 40% sialylated oligosaccharides 
(Karlsson et al., 1997). MUC2 expression is heavily upregulated during inflammatory processes or 
infection, mainly due to activation by IL-4 and IL-9 (Lillehoj & Kim, 2002). The ASL contains also 
other defense-related proteins, such as protease-inhibitors, anti-oxidants, proteases, anti-microbial 
proteins, IgA and cytokines (Lillehoj & Kim, 2002). The high concentrations of IgA in the mucus are 
indicative of an early infection, suggesting that antibodies and immunoglobulins are secreted in the 
mucus to fight the initial phases of infection (Kreijtz et al., 2011).  
 
Some proteases were shown to activate influenza virus, and are possibly responsible for the 
pneumopathogenicity of the virus (Lillehoj & Kim, 2002). Mucins showing anti-protease activity 
(Nadziejko & Finkelstein, 1994), seem to improve the host defense system. Nicholls et al. (2007) 
hypothesized that the high content of sialylated proteins in the secreted mucus is a physical barrier to 
the influenza virus, preventing the virus from accessing target epithelial cells. The physiological role 
of cellular sialic acid receptors is to promote mucus adherence to the epithelial cell surface that 
protects epithelial tissues from dehydration, microbial pathogens, and reactive oxygen species 
produced by infectious bacteria and/or the oxidative burst of leucocytes (Ogasawara et al., 2007). 
However, sialoglycoproteins mediating the cell adherence and viscoelasticity of mucus, and serve as 
receptor sites for the binding of exogenous macromolecules, including influenza virus HA.  
The mucus line of defense comprises a viscoelastic gel up to 50μm thick, immobilizing bacteria and 
viruses, that are then cleared by the cilia action of ciliated cells of the respiratory tract. The enhanced 
defence is probably due also to the soluble sialylated proteins in the mucus, that mimic the natural 
ligands of influenza on the cell surface, that immobilize virus on the mucus layer (Duez et al., 2008; 
Cohen et al., 2013). They found that the higher the concentration of sialic acids in the mucus, the less 
epithelial cells were infected in vitro, especially if the mucus samples are treated with the 
neuraminidase (NA) inhibitor oseltamivir phosphate. The virus could find its way through the mucus 
layer towards epithelial cells in the absence of oseltamivir, since NA is able to free the virus entangled 
in mucus by disrupting the binding of the virus HA to sialic acid. The rate of virions clearance 
depends on the interactions of motile cilia from the trachea with the overlaying mucus. It is not yet 
clear what determines the rates of mucociliary clearance, which vary within proximal and distal 
regions of the airways. Certainly, the effeicacy of cilia are primary determinants of the basal 
mucociliary clearance rate, but the quantity and viscoelastic properties of mucin may also be important 
variables (Knowles & Boucher, 2012). 
Moreover, proteins with CRDs are also likely to interact with HA and NA, since those two viral 
proteins have N-linked oligossaccharides side chains. Yang et al. (2011) showed that Galectin-1 can 
bind influenza virus and inhibit viral infection both in vitro and in mice. The authors observed that the 
galectin-1 expression is upregulated in animals during ongoing infection in a viral-load-dependent 
manner (the larger the viral load, the more galectin-1 expressed). Also, mice that were infected with a 
neurovirulent strain of influenza-A virus showed a higher rate of survival when treated with galectin-1 
intranasally, and with a lower degree of apoptosis and inflammation in the lungs, showing that 
galectin-1 is an effective inhibitor of viral reproduction and reduces the symptoms of infection. 
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Inside a host cell: innate immune response to influenza virus infection. 
The innate immune system constitutes the first line of defense against a viral infection (Fig. 2). 
During this phase, epithelial host cells can recognize novel influenza infection via pattern recognition 
receptors (PRRs). PRRs recognize pathogen-associated molecular patterns (PAMPs) expressed during 
virus replication (Hale et al., 2010). The principal PAMP for influenza is the viral RNA bearing a 5’-
triphospate group (PPP-RNA), which constitutes a molecular signature that distinguishes foreign RNA 
from host RNA (Abbas et al., 2013). The receptors able to sense the viral RNA are: toll-like receptors 
(TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs) (Pang & Iwasaki, 2011), and 
interferon-induced proteins with tetratricopeptide repeats (IFITs, Abbas et al., 2013). 
The major function of these receptors is to initiate expression of pro-inflammatory cytokines and 
type-I interferons: IFN-α and IFN-β (Heil et al., 2004; Lund et al., 2004), that are able to inhibit 
protein synthesis in host cells, limiting the replication of viruses. They also stimulate dendritic cells 
(DCs) to enhance both CD4+ and CD8+ antigen presentation, thus promoting activation of the 
adaptive immune response (Kreijtz et al., 2011). The innate cellular response to viral infection is 
mainly carried out by macrophages and DCs. Alveolar macrophages (AM) have somewhat opposing 
effects after becoming activated in the host’s lungs. On the one hand, they phagocytose influenza 
virus-infected cells, thus limiting viral spread (Tumpey et al., 2005; Kim et al., 2008); and on the 
other, they produce nitric oxide synthase 2 (NOS2) and tumor necrosis factor alpha (TNF-α), thus 
contributing to influenza virus-induced pathology (Jayasekera et al., 2007; Lin et al., 2008). These 
competing effects clearly underscore the delicate equilibrium that exists within the immune system. 
Another AM role is in regulating the immune response, especially in the development of antigen-
specific T-cell immunity (Wijburg et al., 1997). Of note, while AM produce only low levels of pro-
inflammatory cytokines (van Riel et al., 2011), blood-derived macrophages infected with influenza 
viruses produce large amounts of pro-inflammatory cytokines. 
Receptors I: Toll-like receptors (TLR) 
Toll-like receptors (TLRs) are a highly conserved family of PRRs glycoproteins and play a pivotal 
role in the innate immune recognition of viruses (Fig. 2). TLRs consist of an N-terminal extracellular 
PAMP-binding domain with multiple leucine-rich repeats (LRRs) linked by a transmembrane domain 
to a cytosolic C-terminal intracellular signaling domain called Toll/IL-1R homology (TIR). TIR 
domain is named after its similarity to the intracellular domain of the interleukin-1 receptor (IL-1R) 
that mediates down-stream signaling events upon activation of the receptor (Jensen & Thomsen, 
2012). TLR activation triggers a signal cascade involving adaptor proteins, protein kinases, and 
effector transcription factors, and mainly results in the production of type I IFN (e.g., IFN-beta). These 
processes induce an antiviral cellular state, providing an important first line of defense against virus 
infection. Others TLR-triggered proinflammatory cytokines (e.g. TNF and IL-6) are also important 
determinants of the balance between beneficial host innate immune responses and immunopathology.  
Ten known TLR (TLRs 1–10) have been identified in humans. Among them TLR3, 7, 8 and 10 are 
known to recognize influenza virus infection (Koyama et al., 2007; Le Goffic et al., 2007; Lee et al., 
2014). TLR7 and TLR8 share the highest degree of sequence similarity and sense ssRNA 
oligonucleotides containing guanosine and uridine-rich sequences. TLR7 is preferentially expressed in 
the endosomes of plasmacytoid dendritic cells (pDCs) and B cells, while TLR8 is preferentially 
expressed in myeloid DCs and monocytes. Upon stimulation, TLR7 and TLR8 recruit a TIR-
containing adaptor named myeloid differentiation primary response gene 88 (MyD88) to the 
cytoplasmic TIR domain of the receptor (Medzhitov et al., 1998). This signaling pathway leads to the 
activation of either NF-κB/AP-1 or NF-κB/AP-1/IRF7 complexes, which result in the transcription of 
proinflammatory cytokines and INF-α genes, respectively. TLR3 is localized in the intracellular 
compartment of macrophages, B lymphocytes, and DCs. It is located both intracellularly and on the 
surface of NK cells, epithelial cells, and fibroblasts. It recognizes viral dsRNA expressed in some 
viruses, leading to the activation of NF-κB/AP-1/IRF3 complexes and upregulation of IFN-β (Jensen 
& Thomsen, 2012). Recent studies reported an upregulation of human TLR10 expression upon 
influenza H5N1 viral infection, especially in primary macrophages. These data suggest that TLR10 is 
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able to substantially enhance vRNP-induced activation of IL-8 expression (Lee et al., 2014). 
 
 
Figure 2  Escape from adaptive response.  
Upon influenza virus infection, viral RNA is sensed and  several pathways are activated. This results in the production 
of type-I interferons, pro-inflammatory cytokines and induction of an antiviral state. Influenza virus proteins interact 
with this pathway. NS1 binds viral RNA to mask detection by PRRs. It blocks RIG-I activation by binding TRIM25 
and also binds PKR and inhibits its phosphorylation, which occurs when PKR binds viral RNA. NP interacts with the 
P58IPK/hsp40 complex upon which P58ipk is dissociated from the complex and inhibits the phosphorylation of PKR. 
M2 on the other hand restores the P58IPK /hsp40 complex resulting in the inhibition of protein synthesis and induction 
of cell apoptosis, facilitating release of virus particles. PB1-F2 binds mitochondrial antiviral signaling protein (MAVS), 
thereby inhibiting this protein and type-I interferon production. PB2 also binds MAVS and inhibits its function. 
Furthermore, PB2 binds interferon promoter stimulator 1 (IPS-1), resulting in inactivation of the promoter that would 
lead to production of type I interferon. Dotted arrows represent pathways and solid lines and arrows represent direct 
interactions. 
Receptors II: RIG-I-like receptors (RLRs) 
The RIG-I-like receptors (RLRs) are cytosolic proteins that recognize viral RNA and are expressed 
by most human cell types (Fig. 2). They share a conserved domain structure, characterized by a central 
DExD/H-box helicase domain and a ssRNA/dsRNA (ss/dsRNA)-binding C-terminal domain (CTD) 
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which, when unbound, functions as a repressor domain (RD) (Gack, 2014). Three RLRs  are known to 
be directly implicated in viral recognition: the retinoic acid-inducible gene I product (RIG-I, encoded 
by the DDX58 gene), the laboratory of genetics and physiology 2  (LGP2, encoded by the DHX58 
gene) and the melanoma-differentiation-associated antigen 5 (MDA5). RIG-I and MDA5 harbor two 
N-terminal caspase activation and recruitment domains (CARDs) which, upon virus sensing, initiate 
downstream signaling, eventually leading to type I IFN gene expression. In contrast, LGP2 lacking the 
CARD signaling module has been shown to exert a regulatory role in RLR signaling, although its 
precise mechanism of action is still largely unknown (Kato et al., 2006).  RIG-I and LGP2 have been 
reported to play an important role in influenza virus RNA recognition, yet MDA5 recognizes also the 
viral RNA of other pathogens (Jensen & Thomsen, 2012). Recent studies revealed that RIG-I activity 
is tightly regulated by post-translational modifications; in particular, the dephosphorylation of CTD 
(Thr770, Ser854/855) and CARD (Ser8, Thr170) and their subsequent poly-ubiquitination at Lys63 
and Lys172, respectively. Ubiquitin-bound CARDs facilitate RIG-I oligomerization and binding to 
MAVS, ultimately inducing antiviral signaling. (Gack, 2014).  
Receptors III: NOD-like receptors (NLRs) 
Nucleotide-binding oligomerization domain–containing (NOD)-like receptors (NLR) are cytosolic 
proteins involved in the regulation of inflammatory and apoptotic responses, in particular during anti-
viral responses (Fig. 2). NLRs contain a leucine-rich-repeat (LRR) domain located at the C-terminus 
and which is considered to be the RNA sensing region. The central NACHT domain mediates 
oligomerization and activation, while the N-terminal effector-binding domain, often a CARD or pyrin 
domain (PYD), upon activation and oligomerization of the whole NLR triggers the signal transduction 
cascade (Fritz et al., 2006). Among NLRs, both NLRC2 (also named NOD2) and NLRP3 are involved 
in influenza virus RNA-sensing. 
NLRC2, that contains two CARD domains at the N-terminus (Ogura et al., 2001), is a NOD-like 
receptor family member that was recently shown to recognize ssRNA species derived from either one 
of RSV, parainfluenza virus and influenza-A virus. Upon viral ssRNA recognition, NLRC2 associates 
with MAVS (encoded by the VISA gene) through an interaction dependent on the LRR and 
nucleotide-binding domains (NBDs). This initiates the MAVS-dependent pathway (similar to the 
RLRs mechanism previously indicated) culminating with the expression of type-I IFN and 
proinflammatory cytokines. In contrast to RLRs, the NLRC2 interaction with MAVS doesn’t involve 
CARD-CARD binding (Sabbah et al., 2009). NLRP3 (for NOD-like receptor family pyrin domain-
containing 3) contains a pyrin domain (PYD) that can interact with the N-terminal PYD domain of 
apoptosis-associated speck-like protein (ASC) containing a CARD domain. NLRP3 oligomerizes and 
recruits ASC and a procaspase-1 to form an inflammasome complex. This activates caspase-1, which 
subsequently mediates the conversion of pro-IL-1beta and pro-IL-18 to fully functional IL-1beta and 
IL-18. Activation occurs also upon infection with adenovirus, Sendai virus (ssRNA virus) and 
influenza virus A (Allen et al., 2009; Ichinohe et al., 2009). 
Interferon-induced proteins with tetratricopeptide repeats (IFITs) 
IFITs are effectors within the innate immune system that seem to confer virus defense via 
disruption of protein–protein interactions in the host translation-initiation machinery. However, IFITs 
can directly recognize viral RNA bearing a 5’-triphosphate group (5’-PPP-RNA). IFIT1, and IFIT5 in 
particular, were shown to actively and selectively bind cytosolic 5’-PPP-ssRNAs. These results were 
confirmed by structural analysis (Pichlmair et al., 2011; Abbas et al., 2013). 
Viral escape from innate immunity  
Two evolutionary processes are involved in viral evolution and in the evasion by the host immune 
system: antigenic drift of the influenza viral genome and the high selective pressure generated by the 
human immune response (Fig. 2). These escape mechanisms involve the interaction between protein 
viral effectors and some human targets. The influenza virus NS1 protein can bind viral RNA, masking 
it from TLRs/RIG-I recognition, thus inducing expression of INF type I (Garcia-Sastre, 2004; Guo et 
al., 2007). NS1 proteins can also inactivate RIG-I binding to the tripartite-motif-containing protein 25 
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(TRIM25) and inhibit the ssRNA-binding protein kinase (PKR), encoded by the EIF2AK2 gene (Tan 
& Katze, 1998; Garcia-Sastre, 2004; Gack et al., 2009). In addition, both the influenza virus 
nucleoprotein (NP) and the ion channel protein M2 can bind and inactivate the cellular inhibitor 
P58IPK, encoded by the DNAJC3 gene, and the P58IPK/hsp40 complex respectively. These effectors 
are both critical for the regulation of PKR, and their inactivation results in the inhibition of protein 
synthesis, induction of cell apoptosis, and release of newly formed virus particles (Guan et al., 2010). 
Table 2 presents the variability of host genes involved in viral escape mechanisms. The EFI2AK2 
(another PKR) gene is the most variable gene among the four selected viral escape genes. As expected, 
the majority of variation is observed in the non-coding regions. In the coding region, the majority of 
the observed variation derives from single mutations (synonymous and non-synonymous). 
Table 2. Host genes involved in viral escape mechanisms. DNAJC3 (encodes the inhibitor P58IPK); 
EIF2AK2 (encodes PKR); TRIM25 (encodes the tripartite-motif-containing protein 25); VISA 
(encodes the MAVS protein) 
Type of variant DNAJC3 EIF2AK2 TRIM25 VISA SUM 
Frameshift coding 0 0 0 0 0 
Non-synonymous coding 2 15 4 16 37 
Splice site 0 8 0 4 12 
Synonymous coding 5 16 3 6 30 
Intronic 29 177 9 49 264 
5' UTR 2 24 1 0 27 
3' UTR 3 67 24 15 109 
Upstream 2 5 0 0 7 
Downstream 3 3 0 0 6 
Other* 0 2 0 0 2 
Total number of variants 46 315 41 90 492 
 
The genetic variants described in the 1000 Genomes Project Pilot data are: Frameshift coding: structural mutation in coding sequence, resulting in a frame shift 
of reading (A, B); Non-synonymous coding: nucleotide substitution in the coding sequence (A, B), resulting in an amino acid change in the peptide chain (A, C); 
Splice Site: 1-3bp into an exon or 3-8bp into an intron (A); Synonymous coding: nucleotide substitution in coding sequence (A, B), but not resulting in an amino 
acid change (C); Intronic: mutation in intron (A); 5'UTR: in 5’ untranslated region (A, B); 3'UTR: in 3’ untranslated region (A, B); Upstream: mutation within 
5kb upstream of the 5' end of transcript (A); Downstream: mutation within 5kb downstream of the 3' end of transcript (A).
Mutations related to influenza infection 
Although the variability of the genes involved in innate immune response could have an important 
impact on the outcome of infection, our understanding of how genetic variability correlates with 
susceptibility to infection is still very limited and, in general, not supported by experimental 
approaches.  
A missense mutation (F303S) in the Toll-like receptor 3 (TLR3) gene has been linked to influenza-
associated encephalopathy (IAE), a severe neurological condition (Esposito et al., 2012). F303S TLR3 
receptor was shown to be less effective in activating the transcription factor, NF-κB, as well as 
triggering downstream signaling via the IFN beta receptor (Esposito et al., 2012). An additional TLR3 
SNP (rs5743313) was identified in a study of 51 children with confirmed H1N1 infection (Esposito et 
al., 2012).  The rs5743313C/T genotype was found in 18/18 children with IAV-associated pneumonia, 
but significantly less frequently in children with IAV without pneumonia (p < 0.0001), further 
demonstrating the association between TLR3 and IAV pathogenicity. Searching the 1000 Genomes 
Project database for such TLR3 variants, we found that none of the studied individuals carried the 
F303S mutation. In scope of this search we were not able to confirm that individuals with the 
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rs5743313C/T genotype went through acute pneumonia related to influenza-A infection (Esposito et 
al., 2012). On the other hand, we were able to see that the frequencies of each allele were similar 
between populations, with the C allele having a frequency of more than 80%, suggesting that around 
32% of individuals in the samples could possibly have the C/T genotype assuming that the population 
is in Hardy-Weinberg Equilibrium. Nonetheless, four populations of the 1000 Genomes Project were 
outside of this range of frequency for the C allele, namely—British (GBR, C=76% - 36% C/T 
genotype), Iberic (IBS, C=67% - 44% of C/T genotype), Puerto Ricans (PUR, 71% - 41% C/T 
genotype), and Toscani in Italy (TSI, C=69% - 43% C/T genotype), which indicates that those 
populations could be more susceptible to a more severe manifestation of the influenza infection, since 
the possibility of heterozygosity enhances when C and T allelic frequencies are similar. The Japanese 
population (JPT, C=97,8% - 4,3% C/T genotype) had the highest frequency of the C allele detected in 
the 1000 Genomes Project database, indicating that possibly only 4.3% of the population might be 
susceptible to acute pneumonia associated with IAV infection.  
Four single nucleotide polymorphisms (SNPs) that showed association with severe illness were 
identified in a case-control association study on 91 patients with confirmed H1N1 infection–induced 
pneumonia (Mänz et al., 2013). The first SNP was located in the genetic locus for the Replication 
Protein A Interacting Protein (RPAIN). RPAIN facilitates the nuclear localization of RPA, a key 
protein in maintaining DNA integrity and homeostasis. The second SNP was found in the 
Complement component 1 gene coding for a subcomponent binding protein (C1QBP) gene. C1QBP 
inhibits the complement activation. The third SNP was found within the gene encoding the CD32 (also 
called FCGR2A). The CD32 is a cell surface receptor with low affinity for IgG, it is found on 
phagocytic cells such as macrophages and neutrophiles that are involved in the process of 
phagocytosis and clearing of immune complexes. The last SNP was located within the potentially 
intergenic region of chromosome 3. Since two of these SNPs are associated with the genes whose 
products take part in either the clearing of immune complexes (FCGR2A), or in complement 
activation (C1QBP), it is reasonable to hypothesize that the severe disease outcome of H1N1 infection 
may result from variation in the host’s immune response. 
A new study reports a direct association between polymorphisms of rs17561 in the IL1A gene and 
rs1143627 in the IL1B gene and higher susceptibility to A(H1N1) infection (Liu et al., 2013). 
Interleukins IL1A and IL1B are very important in influenza infection, as both induce the expression of 
a variety of inflammatory mediators that may initiate the cascade of inflammatory responses and 
activation of T cells (Acosta-Rodriguez et al., 2007). IL1B has been demonstrated to mediate acute 
pulmonary inflammation, which is one of the main causes of death related to influenza-A virus, while 
IL1A secretion is regulated by the NLRP3 inflammasome (Schmitz et al., 2005; Dawood et al., 2012; 
Gross et al., 2012). The rs17561T variant in the IL1A gene is present in low frequencies in the 1000 
Genomes Project samples. The frequency of this allele ranges from 6% (in Southern Han Chinese) to a 
maximum of 35% (in British samples).  The European samples (Iberian, British, Europeans residents 
in Utah, Toscani and Finnish) showed the highest frequencies of the T allele associated with the higher 
susceptibility to H1N1 influenza-A infection. The SNP rs1143627C in the IL1B gene is very frequent 
in all populations in the 1000 Genomes Project, but in particular among Mexicans, Puerto Ricans, 
Luthya from Kenya, and Yoruba from Nigeria, ranging from 52% in Mexicans to 75% in Luhya. In 
other populations, the frequencies range from 21% (in Iberians), to 48% (in Americans of African 
descent). If such SNPs strongly influence susceptibility to influenza-A infection, the high frequencies 
might explain rapid spread and the acute respiratory inflammation among human populations. 
The mechanisms of RNA sensing and pattern recognition are very important in the first phase of 
infection. Mutations in the genes that encode pattern-recognizing proteins could prevent a successful 
recognition of pathogen patterns. It is striking that a low number of mutations in these genes is  
observed, as shown in Table 3. Most of the variation is located in intronic regions, which may be 
neutral to the function of the expressed products. This is not true for the TLR genes, where both non-
synonymous and synonymous modifications are predominantly in coding regions, which may 
probably reflect evolutionary increase in the types of patterns recognized.  
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Table 3. List of variants within genes involved in the innate immune response to influenza virus 
infection (the data retrieved from the 1000 Genomes Project database) 
Type of variant DDX58 DHX58 NLRP3 NOD2 IFIT1 IFIT5 TLR3 TLR7 TLR8 TLR10 SUM 
Frameshift coding 3 1 0 2 1 0 1 1 0 2 11 
Non-synonymous coding 30 8 42 28 5 5 10 11 10 34 183 
Splice site 3 3 3 0 0 1 1 0 2 0 13 
Synonymous coding 24 1 54 13 6 2 10 6 33 22 171 
Intronic 124 22 234 16 0 2 10 1 0 12 421 
5' UTR 12 2 40 3 1 0 4 0 1 8 71 
3' UTR 43 0 55 10 1 26 1 13 27 12 188 
Upstream 1 0 3 1 6 1 1 0 4 6 23 
Downstream 5 0 5 0 3 1 1 0 2 8 25 
Other* 1 0 0 0 0 0 1 1 0 4 7 
Total number of variants 246 37 436 73 23 38 40 33 79 108 1113 
*Essential Splice Site (DDX58); Stop Gained   (TLR3, TLR7, TLR10). The genetic variants described in the 1000 Genomes Project Pilot data are: Frameshift 
coding: structural mutation in coding sequence, resulting in a frame shift of reading (A, B); Non-synonymous coding: nucleotide substitution in the coding 
sequence (A, B), resulting in an amino acid change in the peptide chain (A, C); Splice Site: 1-3bp into an exon or 3-8bp into an intron (A); Synonymous coding: 
nucleotide substitution in coding sequence (A, B), but not resulting in an amino acid change (C); Intronic: mutation in intron (A); 5'UTR: in 5’ untranslated 
region (A, B); 3'UTR: in 3’ untranslated region (A, B); Upstream: mutation within 5kb upstream of the 5' end of transcript (A); Downstream: mutation within 
5kb downstream of the 3' end of transcript (A).
Infection spread: adaptive immune response to influenza virus 
The adaptive phase of the immune response to influenza virus is crucial for the effective fight 
against infection, and can be divided into humoral and cellular immune response (Fig. 3). The humoral 
immune response is characterized by the degradation of viral proteins into peptides, further shown on 
the cell surface of antigen-presenting cells (APC) in complex with human leucocyte antigen (HLA) 
class-II proteins. The HLA class-II–epitope complexes interact with CD4+ T-cells, which in turn 
trigger the production of virus-specific antibodies. In contrast to the humoral response, the cellular 
immune response results in the activation of naïve CD8+ T cells and their differentiation into 
cytotoxic T lymphocytes (CTLs). Immunoproteasomes present in the host cell cytosol degrade viral 
proteins into peptides that are then transported to the endoplasmic reticulum (ER) via TAP (transporter 
of antigen processing), where they are loaded onto HLA class-I molecules. HLA class-I–epitope 
complexes are then transported via the Golgi to the cell membrane, where they can be recognized by 
virus-specific CTLs (Guermonprez et al., 2002). The CTLs are able to kill the infected cells, thus 
limiting the spread of the virus. 
Humoral immune response to influenza virus 
Elderly people exposed to influenza-A/H1N1 virus in the 1950s were relatively spared from 
infection during the 2009 pandemic strain, since they have developed cross-reactive antibodies (Yu et 
al., 2008; Hancock et al., 2009). This observation suggests that the humoral immune system triggers 
long-lasting antibody-mediated protection against influenza strains that resemble the original strain of 
infection. In the humoral adaptive phase of the immune response, B-cells are stimulated by the 
production of influenza-virus-specific antibodies primarily directed against HA, NA and M2 viral 
proteins (Baumgarth et al., 2000; Waffarn & Baumgarth, 2011). Antibodies directed against the 
trimeric globular HA head efficiently block receptor-mediated endocytosis of the virus (De Jong et al., 
2003). However, most of antibodies are strain-specific and fail to neutralize other influenza serotypes 
(Yu et al., 2008). 
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Figure 3  HLA antigen presentation pathways and activation of the adaptive immune 
response 
Both HLA class I and HLA class II presentation pathways are activated during influenza virus infections. HLA class I 
presentation (solid arrows): the epitopes obtained by immunoproteasome degradation of cytosol proteins, are 
transported in the ER via TAP. The HLA class I epitope complexes are then transported to the plasma membrane where 
they stimulate the differentiation of cytotoxic CD8+ T cell (CTL) and provide signaling for the suppression of the 
infected cells by CTL effector (adaptive cellular response). HLA class II presentation (dotted arrows): the epitopes 
obtained from the proteolytic degradation within endosomal compartments are then assembled with HLA class II 
proteins. The HLA class II - epitope complexes are transported to the plasma membrane where they both stimulate the 
differentiation of T-helper CD4+ and activate T-helper effectors triggering the humoral response. Induction of immune 
responses after a primary influenza-A virus infection is indicated by solid arrows. Virus-specific memory cell 
populations upon secondary encounter with an influenza-A virus are indicated by dashed arrows. 
 
Neuraminidase (NA) is a viral glycoside hydrolase which,  catalyzing the hydrolysis of terminal 
sialic acid residues from both newly formed virions and host cell receptors, facilitates the release and 
spread of the newly formed viral particles  (von Itzstein, 2007). Anti-NA antibodies inhibit the 
enzymatic activity of NA thereby limiting viral spread and shorten severity and duration of illness 
(Bosch et al., 2010; Kilbourne et al., 2009). NA-specific antibodies may also contribute to the 
clearance of virus-infected cells by facilitating Antibody-Dependent Cell-Mediated Cytotoxicity 
(ADCC) (Carolien et al., 2012). Tetrameric transmembrane viral protein M2 has ion channel activity 
and plays an important role in unpacking the virus in the endosome (Schnell & Chou, 2008). The 
protective effect of cross-reactive anti-M2 antibodies was first demonstrated in mice after passive 
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transfer of M2-specific monoclonal antibodies (Kim et al., 2013), and is attributed to ADCC activation 
(Mozdzanowska et al., 1999; El Bakkouri et al., 2011). The heterosubtypic protective effect of M2-
specific antibodies most probably stems from strong conservation of M2 protein sequence among 
different influenza virus strains (Tompkins et al., 2007; Fiers et al., 2009; Fu et al., 2009; Schotsaert et 
al., 2009; Wang et al., 2009; Ebrahini & Tebianian, 2011). 
The humoral response induces the production of antibodies targeting other viral proteins, including 
the highly conserved NP protein (Carragher et al., 2008). Although NP-specific antibodies are non-
neutralizing to viruses, there is some evidence that they contribute to establishing protective immunity 
(Lamere et al., 2011; Carragher et al., 2008). Their mode of action may include ADCC of infected 
cells and opsonisation of NP, resulting in improved T-cell responses (Bodewes et al., 2010; Sambhara 
et al., 2001). However, the protective effect of non HA/NA antibodies is still under debate. 
The IgA, IgG and IgM antibody isotypes are induced upon primary influenza virus infection, 
whereas IgM responses are not observed after secondary infection (Carolien et al., 2012). Virus-
specific serum IgA responses seem indicative for recent infection with influenza virus (Voeten et al., 
1998; Koutsonanos et al., 2011), while virus-specific IgG antibodies correlate with long-lasting 
protection, whereby these antibodies match the strains causing the infection (Koutsonanos et al., 2011; 
Onodera et al., 2012). IgM antibodies can neutralize the virus but also activate the complement system 
(Jayasekera et al., 2007; Fernandez Gonzalez et al., 2008).  In addition to serum antibodies, influenza 
virus infection also induces local mucosal secretory IgA antibody responses aimed at protecting 
airway epithelial cells from infection (Onodera et al., 2012). 
Cellular immune response to influenza virus – T Cells CD4+. 
Activation of CD4+ T cells occurs upon recognition of viral epitopes associated with MHC class-II 
molecules and interaction with co-stimulatory molecules on APCs. Naïve CD4+ T cells can 
differentiate into CD4+ Th1 cells or Th2 cells (Fig. 3). Th1 cells are mainly involved in regulation of 
the CTL response (Zhu & Paul, 2010a), and in the induction of memory CD8+ T cells (Riberdy et al., 
2000; Belz et al., 2002; Deliyannis et al., 2002). Th2 cells promote the activation and differentiation 
of B-cells, resulting in antibody production (Zhu & Paul, 2010b; Okoye & Wilson, 2011). Two 
different processes, namely antibody class-switching and somatic hypermutation determine the affinity 
maturation of the influenza-specific antibodies, drastically empowering their efficiency 
(Kamperschroer et al. 2006).  Memory CD4+ T cells, induced after a primary influenza-A virus 
infection, contribute to a faster control of subsequent influenza-A virus infections (Strutt et al., 2010). 
Lung resident memory CD4+ T cells in particular have an important role in protection against 
secondary influenza-A infection. 
Cellular immune response to influenza virus – T Cell CD8+. 
The activation of CD8+ T cells occurs upon recognition of viral epitopes associated with MHC 
class-I molecules on APCs in the draining lymph nodes. This process leads to the differentiation of 
CD8+ T into cytotoxic T lymphocytes (CTLs), which migrate to the site of infection in order to 
recognize and eliminate the host cells infected by the influenza virus, thereby preventing the 
production and spread of progeny virus (Nakanishi et al., 2009). The interaction of T-cell receptor 
(TCR) with the HLA class-I–epitope complex stimulates CTLs to release perforin and granzymes, 
causing the apoptosis of infected cells (Andrade, 2010; Moffat et al., 2009). Proinflammatory 
cytokines like TNF-alpha, which inhibit virus replication and enhance lytic activity (La Gruta et al., 
2004; La Gruta et al., 2007; Metkar et al., 2008; Andrade, 2010; van Domselaar & Bovenschen, 
2011), are also produced. After infection, the formation of a pool of memory CD8+ T cells occurs, 
constituting the basis for strong and fast recall responses upon secondary infections (Zimmermann et 
al., 1999; Chang et al., 2007; Hikono et al., 2007; DiSpirito & Shen, 2010; van Gisbergen et al., 
2011). Virus-specific CTLs are mainly directed against epitopes present within highly conserved viral 
proteins, such as NP, M1 and PA. This implies an efficient cross-reactivity that allows the CTLs to 
attack cells infected by different influenza-A subtypes (Assarssen et al., 2008; Kreijtz et al., 2008; Lee 
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et al., 2008). Studies on mice confirmed this hypothesis, showing that CD8+ T cells contribute to both 
homo- and heterosubtypic immunity (Kreijtz et al., 2007; Grebe et al., 2008; Kreijtz et al., 2009; 
Hillaire et al., 2011a; Hillaire et al., 2011b).  
However, the evidence of CTL-induced immune protection against influenza in human is still very 
limited. The presence of heterosubtypic memory CD4+ and CD8+ T cells against the 2009 pandemic 
H1N1 virus was detected in naïve individuals (Sridhar et al., 2012). More circumstantial evidence for 
a protective role for CD8+ T cells in heterosubtypic influenza infections stems from epidemiological 
studies. People who had a symptomatic influenza-A infection with the H1N1 strain prior to the 1957 
pandemic were partially protected from infection with the pandemic H2N2 strain. A similar trend was 
found in isolated infections with the H5N1 (Carolien et al., 2012). 
Genetic variability in the adaptive immune response 
The genetic variability of HLA genetic loci is known to be very large in any given population (c.f. 
Table 3). HLA hyper-variability is in fact the basic mechanism used by the host to ensure the 
recognition of potentially dangerous non-self molecules, triggering activation of the adaptive immune 
response against these molecules (Tables 4A and 4B). The recognition of the HLA-epitope complexes 
by T cell receptor (TCR) is crucial for activation of the adaptive immune response. With this degree of 
genetic variability, it is extremely difficult to associate single HLA mutations with a differential 
response to influenza virus infection. Usually entire HLA alleles or specific allele combinations are 
considered, as they are more likely to be associated with specific phenotypic effects.  Mutations in 
these regions could either prevent the formation of HLA-epitope complexes (Price et al., 2000; Voeten 
et al., 2000; Berkhoff et al., 2004; Rimmelzwaan et al., 2004; Berkhoff et al., 2007a) or cause the 
epitope to escape recognition by TCR, since the epitope no longer matches the specificity of the TCR 
(Price et al., 2000; Boon et al., 2002; Berkhoff et al., 2007a; Berkhoff et al., 2007b). 
Table 4A. Genetic variability within the three principal genetic loci of classic HLA class-I genes (the 
data retrieved from the 1000 Genomes Project database) 
Type of variant HLA-A HLA-B HLA-C SUM 
Essential splice site 34 10 12 56 
Stop Gained 71 26 23 120 
Frameshift coding 577 127 94 798 
Non-synonymous coding 1232 382 857 2471 
Splice site 206 28 48 282 
Synonymous coding 486 148 339 973 
Intronic 1519 557 1230 3306 
5' UTR 74 28 8 110 
3' UTR 909 191 268 1368 
Upstream 60 14 34 108 
Downstream 70 60 59 189 
Total number of variants 5133 1535 2937 9605 
 
The genetic variants described in the 1000 Genomes Project Pilot data are: Frameshift coding: structural mutation in coding sequence, resulting in a frame shift 
of reading (A, B); Non-synonymous coding: nucleotide substitution in the coding sequence (A, B), resulting in an amino acid change in the peptide chain (A, C); 
Splice Site: 1-3bp into an exon or 3-8bp into an intron (A); Synonymous coding: nucleotide substitution in coding sequence (A, B), but not resulting in an amino 
acid change (C); Intronic: mutation in intron (A); 5'UTR: in 5’ untranslated region (A, B); 3'UTR: in 3’ untranslated region (A, B); Upstream: mutation within 
5kb upstream of the 5' end of transcript (A); Downstream: mutation within 5kb downstream of the 3' end of transcript (A). 
 
Mutations within viral epitopes were shown to have a direct effect on the efficiency of CTL 
response (Carolien et al., 2012). These types of mutations have been observed in escape mutants of 
viruses that chronically infect their host, like HIV-1 (Huet et al., 1990; Cale et al., 2011). Substitutions 
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of epitopes recognized by CTL have also been observed during the evolution of seasonal A/H3N2 
influenza viruses (Voeten et al., 2000; Rimmelzwaan et al., 2004; Berkhoff et al., 2007a). The R384G 
substitution in the HLA-B*2705-restricted NP383–391 epitope (Voeten et al., 2000) considerably 
affects the human virus-specific CTL response in vitro (Berkhoff et al., 2007a) while the HLA-
B*3501 restricted NP418–426 epitope (Boon et al., 2002; Berkhoff et al., 2007b) displays signs of 
antigenic drift (Boon et al., 2004), explaining the cross-reactivity of CTL against contemporary 
viruses with historic strains (Gras et al., 2010). The variation rate of CTL epitopes could be 
considerably functionally constrained. For instance, the M1 58–66 epitope is highly conserved despite 
its immunodominant nature, probably because mutations within this epitope compromise the virus 
fitness (Berkhoff et al., 2006). 
Table 4B. Genetic variability of HLA class II β-chains within the three principal genetic loci (the data 
retrieved from the 1000 Genomes Project database) 
Type of variant 
HLA-
DPB1 
HLA-
DQB1 
HLA-
DQB2 
HLA-
DRB1 
HLA-
DRB3 
HLA-
DRB5 SUM 
Essential splice site 2 27 0 2 3 5 39 
Stop Gained 12 42 0 4 1 11 70 
Frameshift coding 0 150 0 35 3 24 212 
Non-synonymous coding 176 1071 18 166 89 150 1670 
Splice site 10 138 4 9 2 2 165 
Synonymous coding 69 491 33 90 38 62 783 
Intronic 192 3099 181 267 142 191 4072 
5' UTR 3 60 1 16 13 4 97 
3' UTR 117 633 48 113 86 130 1127 
Upstream 7 100 3 20 15 11 156 
Downstream 9 141 4 28 17 6 205 
Total number of variants 597 5883 292 744 405 580 8501 
 
The genetic variants described in the 1000 Genomes Project Pilot data are: Frameshift coding: structural mutation in coding sequence, resulting in a frame shift 
of reading (A, B); Non-synonymous coding: nucleotide substitution in the coding sequence (A, B), resulting in an amino acid change in the peptide chain (A, C); 
Splice Site: 1-3bp into an exon or 3-8bp into an intron (A); Synonymous coding: nucleotide substitution in coding sequence (A, B), but not resulting in an amino 
acid change (C); Intronic: mutation in intron (A); 5'UTR: in 5’ untranslated region (A, B); 3'UTR: in 3’ untranslated region (A, B); Upstream: mutation within 
5kb upstream of the 5' end of transcript (A); Downstream: mutation within 5kb downstream of the 3' end of transcript (A). 
 
It is noteworthy that the most variable of the non-HLA genes (NLRP3, with 496 variants) are still less 
variable, according to the data from the 1000-genomes Project, than the average for the nine HLA 
genes shown here. The most conserved gene in the HLA system, HLA-DQB2, has 292 described 
variants. The HLA-B gene, on the other hand, has 1,535 variants, which is still lower than that 
recorded by the IPD-TGTM/HLA website, which as (of May 2014) identifies 3,455 alleles, encoding 
2,577 different proteins. Such enormous quantity of variants, underscores the importance of their 
function, since they should attach and present a plethora of possible peptides to cytotoxic and memory 
lymphocytes. The more universal are the HLA molecules, the more efficient will be the peptide 
presentation and the activity of the adaptive immune system. 
 
Concluding remarks 
 
It is more important to know what sort of person has a disease, than to know what sort of 
disease a person has.  – Hippocrates of Cos (c. 460 BC – c. 370 BC) 
 
The initial motivation for this review was the work of Horby et al. (2012), that was concluded with 
an open question: Is susceptibility to severe influenza in humans heritable? – hard to answer, but not 
due to a lack of genotyping or analytic tools, nor because of insufficient evidence from severe 
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influenza cases, but because of the absence of a coordinated effort to define and assemble cohorts of 
cases. Here we presented an update overview of the host variability of genes associated with flu 
infection, and discuss the possible influence of this variability on the severity of flu infection. Each 
virus-host interaction begins with entry of the virus into the host organism, and ends either in death of the 
individual or in elimination of the virus by the immune system. Evolution of the host–pathogen interactions 
yields variants in host genes, several of which are ultimately associated with bad or good prognosis following 
infection, while boosting the host’s future resilience towards given, specific strain subtype of the viral epitopes. 
Even if the severity of infection was mild and/or asymptomatic, these variants have been shown to be 
polymorphic in different human populations, which could be correlated with the different rates of 
morbidity/mortality from the influenza-A infectivity. Therefore, the answer to the Horby et al. (2012) question is 
positive, the susceptibility to severe influenza in humans is heritable. 
On the other hand, it does not mean that all causes and variance in symptomatology and morbidity 
of flu infections have been discovered, or that they are only due to host genetic profile, but there are 
clearly several genes in the human genome that might have a direct impact on the course of influenza-
A infections. In particular, when considering the ethnicity-derived genomic variance, some aspects of 
specific habitats and climates should not be neglected. In temperate regions the peak flu infectivity is 
felt predominantly during the winter months and epidemics recur with a highly predictable seasonal 
pattern. The studies using mouse-adapted strains of influenza virus, with experiments performed in the 
winter months yielded a transmission rate of 58.2%, yet of only 34.1% in summer (Schulman and 
Kilbourne 1963). It has been hypothesized that possible causes of such seasonality include fluctuations 
in host immune efficiency mediated by seasonal factors such as melatonin (Dowell 2001) and vitamin 
D (Cannell et al. 2006) levels; the changes in host behavior (school attendance, indoor crowding, air 
travel, etc.); but in particular environmental factors, including temperature (Eccles 2002), relative 
humidity, and the direction of seasonal winds movement in the upper atmosphere (Hammond et al. 
1989). The role of the South-East Asia region, in particular in countries spanning latitudes from 
subtropical at the south to high-mountainous at the north through several climactic zones, as spawning 
grounds of new flu strains is very well known (see e.g. Le et al. 2013), and a field of intense 
phylogeographical research (Wallace and Fitch 2008, for a review). In contrast, the situation differs in 
the [sub]tropical regions, which experience influenza throughout the year, with somewhat increased 
incidence during rainy seasons (Viboud et al. 2006, Shek and Lee 2003). Such regions, like rainforests 
of equatorial Africa, or Amazonian regions of Brazil, Venezuela and Ecuador, are still potentially rich 
areas for a concerted efforts to connect the possible ethnic genomics factors in isolated communities, 
with the influenza-A prevalence and infectivity patterns.  
Also, many factors can cause modifications in DNA (epigenetic modifications) that alter gene 
expression. Several studies support the theory of prenatal/childhood programming as origin of various 
adult diseases (Nicoletto and Rinaldi, 2011, Ahmed 2010). Epigenetic modifications were described to 
explain adult disease in response to environmental modifications in prenatal or childhood. For 
example, Yang and Huffman (2013) showed that individuals who suffer some sort of nutritional 
privation during gestation tend to become obese adults. It can be thought that if the pattern of 
methylation that is programmed in one's genome during development can affect the way that 
individual will react to a diet as an adult, it might possibly affect the way immune-related genes are 
expressed during infections (Guoying W et al. 2013). 
Very recently the work of Guihot et al. (2014) demonstrated some curious cases that impose more 
questions than answers. The authors have found biological markers that can predict whether an 
individual is more prone to suffer lethal consequences to influenza infection. However, the genetic 
variability that underlies such markers is not well understood – e.g., some of the markers indicated a 
"trapping" antibodies in the lungs for the lethal cases, whilst the survivors had the antibodies freed into 
a blood. In another recent study Worobey et al. (2014) have hypothesized that the high mortality 
during the 1918 Spanish flu pandemic among adults aged ~20 to ~40 years might have been due 
primarily to their childhood exposure to a heterosubtypic putative H3N8 virus – estimated as to have 
been circulating from ~1889–1900. All other age groups (except immunologically naive infants) were 
likely to be partially protected by childhood exposure to N1 and/or H1-related antigens. Such tenet 
poses immediate questions. What possible immunological mechanism[s] already described, might 
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explain such an increase of mortality rates? Especially a mechanism of contrasting the H3 non-naïve 
young-adult Spanish flu victims (but putatively naïve towards H1 serotype), with infants – by 
definition naïve to all HA subtypes. In effect such a mechanism would require a convincingly 
plausible pathway[s] of suppressing immunity specifically by an action of H3-derived epitopes. One 
possible mechanism would be that the exposure to this putative H3N8 virus could have caused a 
methylation pattern in some genes, especially on some paths of imune response, and as consequence 
these patients had an extremely severe flu. Also, maybe not all individuals exposed to this virus 
developed the same methylation patterns and final supressions due to the genetic variability known to 
exist in human populations. The authors postulate that a mechanism akin to original antigenic sin 
(OAS, Francis T, 1960) may have interfered with immune responses in some of those infected in 
1918, and peaked in those exposed previously to the 1889 virus. However, such hypothesis opens 
important questions about possible molecular and immunological mechanisms pertaining to the actual 
OAS phenomena “in action”. It is obvious that many more studies of this type will be necessary to 
better understand how the environment and host genetic variability affects the susceptibility to the 
influenza-A virus. The present review shows that both host genetic variability as well as environment 
are clearly factors of great importance to determine such susceptibility. 
Acknowledgements 
We are grateful to Anna Lisa Lucido (Jackson Laboratory for Genomic Medicine) for her critical 
review of the manuscript. This work was supported by the Polish Ministry of Education and Science 
(grant number NCN 2013/09/B/NZ2/00121). GM was financed by research fellowship within Project 
‘‘Information technologies: Research and their interdisciplinary applications’’,. ACA was supported 
by a doctoral fellowship granted by Coordenação de Aperfeiçoamento Pessoal de Nível Superior, 
CAPES., Brazil. SFO received a fellowship from CNPq (Conselho Nacional de Desenvolvimento 
Científico), Brazil. Additional partial funding was generously provided by the WND-POIG.01.01.02-
00-007/08 grant from the European Regional Development Fund. 
Conflicts of interests 
Authors declare no conflict of interests. 
 
References 
 
1000 Genomes Pilot Browser – pilotbrowser.1000genomes.org/index.html (as of May 2014). 
Abbas YM, Pichlmair A, Górna MW, Superti-Furga G, Nagar B (2013) Structural basis for viral 5'-
PPP-RNA recognition by human IFIT proteins. Nature 494:60-64.  
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but 
not transforming growth factor-beta are essential for the differentiation of interleukin 17-
producing human T helper cells. Nat Immunol 8(9):942–949. 
Ahmed F  (2010) Epigenetics: Tales of adversity Nature 468, S20; doi:10.1038/468S20a. 
Allen IC, Scull MA, Moore CB, Holl EK, McElvania-TeKippe E, Taxman DJ, Guthrie EH, Pickles 
RJ, Ting JPY (2009) The NLRP3 inflammasome mediates in vivo innate immunity to influenza A 
virus through recognition of viral RNA. Immunity 30:556-65. 
Andrade F (2010) Non-cytotoxic antiviral activities of granzymes in the context of the immune 
antiviral state. Immunol. Rev. 235:128–146. 
Andrewes CH (1939) Immunity in influenza: the bearing of recent research work: (section of 
epidemiology and state medicine). Proc. R. Soc. Med. 32(3)145–152.  
Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, Oseroff C, Mbawuike IN, Alexander J, Newman 
MJ, Grey H, et al. (2008) Immunomic analysis of the repertoire of T-cell specificities for influenza 
A virus in humans. J. Virol. 82:12241–12251. 
Bateman AC, Busch MG, Karasin AI, Bovin N, Olsen CW (2008) Amino acid 226 in the 
hemagglutinin of H4N6 influenza virus determines binding affinity for α2,6-linked sialic acid and 
infectivity levels in primary swine and human respiratory epithelial cells. J. Virol. 82(16)8204-09. 
 19
Baumgarth N, Herman O C, Jager G C, Brown L E, Herzenberg L A, Chen J (2000) B-1 and B-2 cell-
derived immunoglobulin M antibodies are non redundant components of the protective response to 
influenza virus infection. J. Exp. Med 192:271–280. 
Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC (2002) Compromised influenza virus-specific 
CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J. Virol. 76:12388-12393. 
Berkhoff EG, de Wit E, Geelhoed-Mieras MM, Boon AC, Symons J, Fouchier RA, Osterhaus AD, 
Rimmelzwaan GF (2006) Fitness costs limit escape from cytotoxic T lymphocytes by influenza A 
viruses. Vaccine 24:6594–6596. 
Berkhoff EG, Boon AC, Nieuwkoop NJ, Fouchier RA, Sintnicolaas K, Osterhaus AD, Rimmelzwaan 
GF (2004) A mutation in the HLA-B*2705-restricted NP383–391 epitope affects the human 
influenza A virus-specific cytotoxic T-lymphocyte response in vitro. J. Virol. 78:5216–5222. 
Berkhoff EG, Geelhoed-Mieras MM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2007a) 
Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by 
using virus-specific CD8+ T-cell clones. J. Gen. Virol. 88:530–53566.  
Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, 
Osterhaus AD, Rimmelzwaan GF (2007b) The loss of immunodominant epitopes affects 
interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T 
lymphocyte response in vitro. Clin. Exp. Immunol. 148:296–306. 
Bodewes R, Osterhaus AD, Rimmelzwaan GF (2010) Targets for the induction of protective 
immunity against influenza A viruses. Viruses 2:166–188. 
Boon AC, de Mutsert G, Graus YM, Fouchier RA, Sintnicolaas K, Osterhaus AD, Rimmelzwaan GF 
(2002) Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A 
virus nucleoprotein associated with escape from cytotoxic T lymphocytes. J. Virol. 76:2567–2572. 
Boon AC, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, Fouchier RA, Sintnicolaas K, 
Osterhaus AD, Rimmelzwaan GF (2004) Recognition of homo- and heterosubtypic variants of 
influenza A viruses by human CD8+ T lymphocytes. J. Immunol. 172:2453–2460. 
Bosch BJ, Bodewes R, de Vries RP, Kreijtz JH, Bartelink W, van Amerongen G, Rimmelzwaan GF, 
de Haan CA, Osterhaus AD, Rottier PJ (2010)  Recombinant soluble, multimeric HA and NA 
exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza 
virus infection in ferrets. J. Virol. 84:10366–10374. 
Brown DM, Dilzer AM, Meents DL, Swain SL (2006) CD4 T cell-mediated protection from lethal 
influenza: Perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 
177:2888–2898. 
Cale EM, Bazick HS, Rianprakaisang TA, Alam SM, Letvin NL (2011) Mutations in a dominant Nef 
epitope of simian immunodeficiency virus diminish TCR-Epitope peptide affinity but not epitope 
peptide-MHC class I binding. J. Immunol. 187:3300–3313. 
Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, et al. (2006) Epidemic influenza and vitamin 
D. Epidemiol Infect 134:1129-1140.  
Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wuethrich I, Godarova A, Kotecki M, Cochran 
BH, Spooner E, Ploegh HL, Brummelkamp TR (2009) Haploid genetic screens in human cells 
identify host factors used by pathogens. Science 326:1231-35. 
Carolien E van de Sandt, Joost H C M Kreijtz, Guus F Rimmelzwaan (2012) Evasion of Influenza A 
Viruses from Innate and Adaptive Immune Responses. Viruses. 4(9)1438–1476. 
Carragher D M, Kaminski D A, Moquin A, Hartson L, Randall T D (2008) A novel role for non-
neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. 
Immunol. 181:4168–4176. 
Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, Tumpey TM, Sasisekharan 
V, Sasisekharan R (2008) Glycan topology determines human adaptation of avian H5N1 virus 
hemagglutinin. Nature Biotechnology 26(1)107-113. 
Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, Banerjee A, Longworth SA, Vinup 
KE, Mrass P, Oliaro J, et al (2007) Asymmetric T lymphocyte division in the initiation of adaptive 
immune responses. Science 315:1687–1691. 
Clarke L, Zheng-Bradley X, Smith R, Kulesha E, Xiao C, Toneva I, Vaughan B, Preuss D, Leinonen 
R, Shumway M, Sherry S, Flicek P, The 1000 Genomes Project Consortium (2012) The 1000 
Genomes Project: data management and community access. Nature Methods 9(5)1-4.  
 20
Cohen M, Varki A (2010) The Sialome – Far more than the sum of its parts. OMICS J Int Biol 
14(4)455-464. 
Cohen M, Zhang XQ, Senaati HP, Chen HW, Varki NM, Schooley RT, Gagneux P (2013) Influenza 
A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol. J. 10:321. 
Cone RA (2009) Barrier properties of mucus. Adv. Drug Deliv. Rev. 61:75-85. 
Das SR, Hensley SE, David A, Schmidt L, Gibbs JS, Puigbò P, Ince WL, Bennik JR, Yewdell JW 
(2010) Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion 
strategy. PNAS Plus early edition:1-6. 
Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, Bandaranayake D, Breiman RF, 
Brooks WA, Buchy P, Feikin DR, Fowler KB, Gordon A, Hien NT, Horby P, Huang QS, Katz 
MA, Krishnan A, Lal R, Montgomery JM, Mфlbak K, Pebody R, Presanin AM, Razuri H, Steens 
A, Tinoco YO, Wallinga J, Vong S, Bresee J, Widdowson MA (2012) Estimated global mortality 
associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a 
modelling study. Lancet Infect. Dis. 12:687-95. 
de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD (2003) 
Haemagglutination-inhibiting antibody to influenza virus. Dev. Biologicals 115:63–73. 
de Wit E, Fouchier R (2008) Emerging influenza. J Clin Virol 4(1)1-6. 
 
Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, Sakabetis E, Brown LE (2002) Induction of 
long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J. 
Virol. 76:4212–4221. 
DiSpirito JR, Shen H (2010) Quick to remember, slow to forget: Rapid recall responses of memory 
CD8+ T cells. Cell Res. 20:13–23. 
Dowell SF (2001) Seasonal variation in host susceptibility and cycles of certain infectious diseases. 
Emerg Infect Dis 7:369-374. 
Duez JM, Sixt N, Péchinot A (2008) Influenza virus infection: don't forget the role of the mucociliary 
system! J. Antimicrobial Chemotherapy. Letter to the Editor. 
Eccles R (2002) An explanation for the seasonality of acute upper respiratory tract viral infections. 
Acta Otolaryngol 122:183-191. 
Ebrahimi S M, Tebianian M (2011) Influenza A viruses: Why focusing on M2e-based universal 
vaccines. Virus Genes 42:1–8. 
El Bakkouri K, Descamps F, de Filette M, Smet A, Festjens E, Birkett A, van Rooijen N, Verbeek S, 
Fiers W, Saelens X (2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza 
A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186:1022–1031. 
El Moussi A, Kacem ABH, Slim A (2014) Loss and gain of N-linked glycosylation sites in globular 
head and stem of HA found in A/H3N2 flu fatal and severe cases during 2013 Tunisia flu seasonal 
survey. Virus Genes 48:189-192. 
Esposito S, Molteni CG, Giliani S, Mazza C, Scala A, Tagliaferri L, Pelucchi C, Fossali E, Plebani A, 
Principi N (2012) Toll-like receptor 3 gene polymorphisms and severity of pandemic 
A/H1N1/2009 influenza in otherwise healthy children. Virol J 9:270. 
Fernandez Gonzalez S, Jayasekera JP, Carroll MC (2008) Complement and natural antibody are 
required in the long-term memory response to influenza virus. Vaccine 26:I86–I93. 
Fiers W, de Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens, X 
(2009) M2e-based universal influenza A vaccine. Vaccine 27:6280–6283. 
Fleischer B (1998) Mechanism of glycosylation in the Golgi Apparatus. The J. of Histochem. and 
Cytochem. 31(8)1033-40.  
Francis T (1960) On the doctrine of original antigenic sin. Proc. Am. Philos. Soc. 104 (6): 572–578. 
Fritz JH, Ferrero RL, Philpott DJ, Girardin SE (2006) Nod-like proteins in immunity, inflammation 
and disease. Nature Immun 7(12)1250-57. 
Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, 
Shiver JW, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein 
ectodomain of influenza A virus. Virology 385:218–226. 
Gack MU (2014) Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens. 
J Virol 88(10)5213-16. 
 21
Gambaryan A, Tuzikov A, Pazynina G, Bovin N, Balish A, Klimov A (2006) Evolution of the 
receptor binding phenotyoe of influenza A (H5) viruses. Virology 344:432-38. 
Garcia-Sastre A (2004) Identification and characterization of viral antagonists of type I interferon in 
negative-strand RNA viruses. In Curr Top Microbiol Immunol 283:249-80. 
Gaunitz S, Liu J, Nilsson A, Karlsson N, Holgersson J (2014) Avian influenza H5 hemagglutinin 
binds with high avidity to sialic acid on different O-linked core structures on mucin-type fusion 
proteins. Glycoconj. J. 31:145-59. 
Glaser L, Conenello G, Paulson J, Palese P (2007) Effective replication of human influenza viruses in 
mice lacking a major α2,6 sialyltransferase. Virus Research 126:9-18. 
Gog JR, Rimmelzwaan GF, Osterhaus AD, Grenfell BT (2003) Population dynamics of rapid fixation 
in cytotoxic T lymphocyte escape mutants of influenza A. PNAS U. S. A. 100:11143–11147. 
Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, Richards MJ, Rimmelzwaan 
GF, Kelso A, Doherty PC, et al. (2010) Cross-reactive CD8+ T-cell immunity between the 
pandemic H1N1–2009 and H1N1–1918 influenza A viruses. PNAS U. S. A. 107:12599–12604. 
Grebe KM, Yewdell JW, Bennink JR (2008) Heterosubtypic immunity to influenza A virus: Where do 
we stand? Microb. Infect. 10:1024–1029. 
Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J 
(2012) Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with 
differential requirement for the protease function of caspase-1. Immunity 36(3):388–400. 
Guan Y, Ranoa DRE, Jiang S, Mutha SK, Li X, Baudry J, Tapping RI (2010) Human TLRs 10 and 1 
share common mechanisms of innate immune sensing but not signaling. J Immunol 184:5094-
5103. 
Guarnaccia T, Carolan LA, Maurer-Stroh S, Lee RTC, Job E, Reading PC, Petrie S, McCaw JM, 
McVernon J, Hurt AC, Kelso A, Mosse J, Barr IG, Laurie KL (2013) Antigenic drift of the 
pandemic 2009 A(H1N1) influenza virus in a ferret model. PloS Pathog 9(5):e1003354. 
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena, S (2002) Antigen presentation and T 
cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667.  
Guihot, A et al. (2014) Low titers of serum antibodies inhibiting hemagglutination predict fatal 
fulminant influenza A (H1N1) 2009 infection. American journal of respiratory and critical care 
medicine, 189 (10) 1240-1249. 
Guo Z, Chen LM, Zeng H, Gomez JA, Plowden J, Fujita T, Katz JM, Donis RO, Sambhara S (2007) 
NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. 
Am. J. Respir. Cell Mol. Biol. 36(3)263–269.  
Guoying W, et al. (2013) Epigenetics and Early Life Origins of Chronic Noncommunicable Diseases, 
Journal of Adolescent Health 52:S14 –S21. 
Hale BG, Albrecht RA, Garcia-Sastre A (2010) Innate immune evasion strategies of influenza viruses. 
Future Microbiol 5(1)23-41. 
Hammond GW, Raddatz RL, Gelskey DE (1989) Impact of atmospheric dispersion and transport of 
viral aerosols on the epidemiology of influenza. Rev Infect Dis 11:494-497.  
Hancock K, Veguilla V, Lu X, Zhong W, Butler E N, Sun H, Liu F, Dong L, DeVos J R, Gargiullo P 
M, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. 
New Engl. J. Med. 361:1945–1952. 
Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P 
(2001) The human sialyltransferase family. Biochimie 83:727-37. 
Harduin-Lepers A, Mollicone R, Delannoy P, Oriol R (2005) The animal sialyltransferases and 
sialyltransferase-related genes: a phylogenetic approach. Glycobiology 15(8):805-817. 
Hatta M, Gao P, Halfmann P, Kawaoka Y (2001) Molecular basis for high virulence of Hong Kong 
H5N1 influenza A viruses. Science 293:1840-42. 
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer 
S (2004) Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. 
Science 303:1526-29. 
 Henn AD, Wu S, Qiu X, Ruda M, Strover M, Yang H, Liu Z, Welle SL, Holden-Wiltse J, Wu H, 
Zand MS (2013) High-resolution temporal response patterns to influenza vaccine reveal a distinct 
human plasma cell gene signature. Scientific Reports 3:2327. 
Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James 
 22
I, Halloran ME, Thomas PG, Corey L (2013) HLA targeting efficiency correlates with human T-
cell response magnitude and with mortality from influenza A infection. PNAS early edition:1-6. 
Hikono H, Kohlmeier J E, Takamura S, Wittmer ST, Roberts AD, Woodland DL (2007) Activation 
phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of 
memory CD8+ T cells. J. Exp. Med. 204:1625–1636. 
Hillaire ML, van Trierum SE, Kreijtz JH, Bodewes R, Geelhoed-Mieras MM, Nieuwkoop NJ, 
Fouchier RA, Kuiken T, Osterhaus AD, Rimmelzwaan GF (2011a) Cross- protective immunity 
against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated 
by virus-specific T-cells. J. Gen. Virol. 92:2339–2349. 
Hillaire ML, Osterhaus AD, Rimmelzwaan GF (2011b) Induction of virus-specific cytotoxic T 
lymphocytes as a basis for the development of broadly protective influenza vaccines. J. Biomed. 
Biotechnol. 2011:939860.  
Horby P, Nguyen NY, Dunstan SJ, Baillie JK (2012) The Role of Host Genetics in Susceptibility to Influenza: A 
Systematic Review. PLoS ONE 7(3):e33180; doi:10.1371/journal.pone.0033180. 
Huet S, Nixon DF, Rothbard JB, Townsend A, Ellis SA, McMichael AJ (1990) Structural homologies 
between two HLA B27-restricted peptides suggest residues important for interaction with HLA 
B27. Int. Immunol. 2:311–316. 
Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A (2009) Inflammasome recognition of influenza 
virus is essential for adaptive immune responses. J Exp Med 206(1)79-87. 
IPD-IGTM/HLA statistics – http://www.ebi.ac.uk/ipd/imgt/hla/stats.html, accessed in May 7th, 2014. 
Jayamaran A, Koh X, Li J, Raman R, Viswanathan K, Shriver Z, Sasisekharan R (2012) 
Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors. Biochem J 
444:429-435. 
Jayasekera JP, Moseman EA, Carroll MC (2007) Natural antibody and complement mediate 
neutralization of influenza virus in the absence of prior immunity. J Virol 81(7)3487-94. 
Jensen S, Thomsen AR (2012) Sensin of RNA viruses: a review of innate immune receptors involved 
in recognizing RNA virus invasion. J Virol 86(6)2900-2910. 
Kamperschroer C, Dibble JP, Meents DL, Schwartzberg PL, Swain SL (2006) SAP is required for Th 
cell function and for immunity to influenza. J. Immunol. 177:5317–5327. 
Karlsson NG, Herrmann A, Karlsson H, Johansson MEV, Carlstedt I, Hansson GC (1997) The 
Glycosylation of rat intestinal Muc2 mucin varies between rat strains and the samll and large 
intestine: A study of O-linked oligossaccharides by a mass spectrometric approach.  J. Biol. Chem. 
272:27025-34. 
Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, 
Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Sousa CR, Matsuura Y, Fujita T, Akira S 
(2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 
44:101-105. 
Kilbourne E.D, Pokorny B.A, Johansson B, Brett I, Milev Y, Matthews J T (2004) Protection of mice 
with recombinant influenza virus neuraminidase. J. Infect. Dis. 189:459–461. 
Kim HM, Lee YW, Lee KJ, Kim HS, Cho SW, van Rooijen N, Guan Y, Seo SH (2008) Alveolar 
macrophages are indispensable for controlling Influenza viruses in lungs of pigs. J Virol 
82(9)4265-74. 
Kim MC, Lee JS, Kwon YM, O E, Lee YJ, Choi JG, Wang BZ, Comans RW, Kang SM (2013) 
Multiple heterologous M2 extracellular domains presented on virus-like particles confer borader 
and stronger M2 immunity than live influenza A virus infection. Antiviral Research 99:328-335. 
Kirkham S, Sheenan JK, Knight D, Richardson PS, Thornton DJ (2002) Heterogeneity of airway 
mucus: variations in the amounts nad glycoforms of the major oligomeric mucins MUC5AC and 
MUC5B. Biochem. J. 361:537-46. 
Kitagawa H, Paulson JC (1994) Differential expression of five sialyltransferase genes in human 
tissues. The J. of Biol. Chem. 269(27)17872-78. 
Knowles MR, Boucher RC (2012) Mucus clearance as a primary innate defense mechanism for 
mammalian airways. J. Clin. Invest. 109:571-77. 
Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondang GCM, Vervaet G, Skepner E, Lewis 
NS, Spronken MIJ, Russell CA, Eropkin MY, Hurt AC, Barr IG, de Jong JC, Rimmelzwaan GF, 
Osterhaus ADME, Fouchier RAM, Smith DJ (2013) Substitutions near the receptor binding site 
 23
determine major antigenic chance during influenza virus evolution. Science 342:976-979. 
Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Jacob J, Prausnitz MR, Compans RW, 
Skountzou I (2011) Serological memory and long-term protection to novel H1N1 influenza virus 
after skin vaccination. J. Infect. Dis. 204:582–591. 
Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, Akira S (2007) 
Differential Role of TLR and RLR-signaling in the immune responses to influenza A virus 
infection and vaccination. J Immunol 179:4711-20. 
Kreijtz JHCM, Bodewes R, van Amerongen G, Kuiken T, Fouchier RAM, Osterhaus AD, 
Rimmelzwaan GF (2007) Primary influenza A virus infection induces cross-protective immunity 
against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25:612–620. 
Kreijtz JHCM, de Mutsert G, van Baalen CA, Fouchier RAM, Osterhaus AD, Rimmelzwaan GF 
(2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte 
populations directed to human influenza A virus. J. Virol. 82:5161–5166. 
Kreijtz JHCM, Bodewes R, van den Brand JM, de Mutsert G, Baas C, van Amerongen G, Fouchier 
RAM, Osterhaus AD, Rimmelzwaan GF (2009) Infection of mice with a human influenza 
A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. 
Vaccine 27:4983–4989. 
Kreijtz JHCM, Fouchier RAM, Rimmelzwaan GF (2011) Immune responses to influenza virus 
infection. Virus Res. 162:19-30. 
La Gruta NL, Turner SJ, Doherty PC (2004) Hierarchies in cytokine expression profiles for acute and 
resolving influenza virus-specific CD8+ T cell responses: Correlation of cytokine profile and TCR 
avidity. J. Immunol. 172:5553–5560. 
La Gruta NL, Kedzierska K, Stambas J, Doherty PC. A question of self-preservation: 
Immunopathology in influenza virus infection. Immunol. Cell Biol. 85:85–92. 
Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, Randall TD, Lund FE, Kaminski DA 
(2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza 
virus clearance. J. Virol. 85:5027–5035. 
Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M, Si-Tahar M (2007) Cutting edge: 
influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral 
responses in human ling epithelial cells. J Immunol 178:3368-72. 
Le MQ, Lam HM, Cuong VD, Lam TTY, et al.  (2013). Migration and persistence of human influenza A 
viruses, Vietnam, 2001–2008. Emerging infectious diseases 19:1756-1765. 
Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, 
Farrar JJ, Smith GL, et al. (2008) Memory T cells established by seasonal human influenza A 
infection cross-react with avian influenza A (H5N1) in healthy individuals. J. Clin. Investig. 
118:3478–3490. 
Lee SMY, Kok KH, Jaume M, Cheung TKW, Yip TF, Lai JCC, Guan Y, Webster RG, Jin DY, Peiris 
JSM (2014) Toll like receptor 10 is involved in induction of innate immune responses to influenza 
virus infection. PNAS 111(10)3793-98. 
Lewallen DM, Siler D, Iyer SS. (2009) Factors affecting protein-glycan specificity: Effect of spacers 
and incubation time. Chem. Bio. Chem. 10:1486-89. 
Lillehoj EP, Kim KC (2002) Airway mucus: its components and function. Arch. Pharm. Res. 
25(6)770-80. 
Lin TY & Brass AL (2013) Host genetic determinants of influenza pathogenicity. Current Opinion in 
Virology 3:531-536. 
Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD (2008) CCR2+ monocyte-derived dendritic 
cells and exudate macrophages produce influenza- induced pulmonary immune pathology and 
mortality. J. Immunol. 180(4)2562–2572.  
Liu Y, Li S, Zhang G, Nie G, Meng Z, Mao D, Chen C, Chen X, Zeng G (2013) Genetic variants in 
IL1A and IL1B contribute to the susceptibility to 2009 pandemic H1N1 influenza A virus. BMC 
Immunology 14:37. 
Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of MicroRNA 
precursors. Science 303:95-98. 
 24
Mänz B, Dornfeld D, Götz V, Zell R, Zimmermann P, Haller O, Kochs G, Schwemmle M (2013) 
Pandemic Influenza A viruses escape from restriction by human MxA through adaptive mutations 
in the nucleoprotein. PLOS Pathogens 9(3)e1003279. 
Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR, Donatelli I, Kawaoka 
Y (2000) Early alterations of the receptor-binding properties of H1, H2 and H3 avian influenza 
virus hemagglutinins after their introduction into mammals. J. Virol. 74(18)8502-12. 
Matrosovich M, Klenk HD (2003) Natural and synthetic sialic acid-containing inhibitors of influenza 
virus receptor binding. Rev. Med. Virol. 13:85-97. 
McKinstry KK, Strutt TM, Swain SL (2011) Hallmarks of CD4 T cell immunity against influenza. J. 
Intern. Med. 269:507–518. 
Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V (1987) Identification of the 
complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. 
J. Exp. Med. 165:848-64. 
Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway Jr CA (1998) 
MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 
2:253-58. 
Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M, Kim S, Raja SM, Shi L, Simon 
MM, et al. (2008) Human and mouse granzyme A induce a proinflammatory cytokine response. 
Immunity 29:720–733. 
Moffat JM, Gebhardt T, Doherty PC, Turner SJ, Mintern JD (2009) Granzyme A expression reveals 
distinct cytolytic CTL subsets following influenza A virus infection. Eur. J. Immunol. 39:1203–
1210. 
Mozdzanowska K, Maiese K, Furchner M, Gerhard W (1999) Treatment of influenza virus-infected 
SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and 
neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254:138–
146. 
Münster AK, Eckhardt M, Potvin B, Mühlenhoff M, Stanley P, Gerardy-Schahn R (1998) Mammalian 
cytidine 5'-monophosphate N-acetylneuraminic acid sinthetase: A nuclear protein with 
evolutionarily conserved structural motifs. Proc. Natl. Acad. Sci. USA 95:9140-45.  
Nadziejko C, Finkelstein I (1994) Inhibition of neutrophil elastase by mucus glycoprotein. Am. J. 
Respir. Cell Mol Biol. 11:103-107. 
Nakanishi Y, Lu B, Gerard C, Iwasaki A (2009) CD8(+) T lymphocyte mobilization to virus- infected 
tissue requires CD4(+) T-cell help. Nature 462:510–513. 
Ng BG, Buckingham KJ, Raymond K, Kircher M, Turner EH, He M, Smith JD, Eroshkin A, 
Szybowska M, Losfeld ME, Chong JX, Kozenko M, Li C, Patterson MC, Gilbert RD, Nickerson 
DA, Shendure J, Bamshad MJ, University of Washington Center for Mendelian Genomics, Freeze 
HH (2013) Mosaicism of the UDP-Galactose Transporter SLC35A2 causes a Congenital Disorder 
of Glycosylation.  The Amer. J. of Hum. Genet. 92:632-36. 
Nicholls JM, Bourne AJ, Chen H, Guan Y, Peiris JSM (2007) Sialic acid receptor detection in the 
human respiratory tract: evidence for widespread distribution of potential binding sites for human 
and avian influenza viruses. Respiratory Research 8:73.  
Nicholls JM, Lai J, Garcia JM (2012) Investigating the interaction between influenza And sialic acid: 
Making and breaking the link. In M von Itzstein (ed.) Influenza Virus Sialidase – A Drug 
Discovery Target..  
Nicoletto SF, Rinaldi A (2011) In the womb’s shadow. EMBO reports 12(1): 30-34. 
Ogasawara Y, Namai T, Yoshino F, Lee MC, Ishii K (2007) Sialic acid is an essential moiety of 
mucin as a hydroxyl radical scavenger. FEBS Letters 581:2473-77. 
Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nuñez G (2001) Nod2, a Nod1/Apaf-1 family 
member that is restricted to monocytes and activates NF-κB. J Biol Chem 276:4812-18. 
Ohuchi M, Ohuchi R, Feldmann A, Klenk HD (1997) Regulation of receptor binding affinity of 
influenza virus hemagglutinin by its carbohydrate moiety. J. Virol. 71(11)8377-84. 
Okoye IS, Wilson MS (2011) CD4+ T helper 2 cells—Microbial triggers, differentiation requirements 
and effector functions. Immunology 134:368–377. 
 25
Olczak M, Maszczak-Seneczko D, Sosicka P, Jakimowicz P, Olczak T (2013) UDP-Gal/UDP-
GlcNAc chimeric transporter complements mutation defect in mammalian cells deficient in UDP-
Gal transporter. Biochem. And Biophys. Res. Commun. 434:473-78. 
OMIM - Online Mendelian Inheritance in Men http://www.omim.org/entry/314375 (accessed in 
29/04/2014). 
Onodera T, Takahashi Y, Yokoi Y, Ato M, Kodama Y, Hachimura S, Kurosaki T, Kobayashi K 
(2012) Memory B cells in the lung participate in protective humoral immune responses to 
pulmonary influenza virus reinfection. Proc. Natl. Acad. Sci. U. S. A. 109:2485–2490. 
Osuka F, Endo Y, Higuchi M, Suzuki H, Shio Y, Fujiu K, Kanno R, Oishi A, Terashima M, Fujita T, 
Gotoh M (2007) Molecular cloning and characterization of novel splicing variants of human 
decay-accelerating factor. Genomics 88:316-22. 
Pang IK, Iwasaki A. Control of antiviral immunity by pattern recognition and the microbiome. Immun 
Rev 245(1)209-226. 
Pichlmair A, Lassnig C, Eberle CA, Górna MW, Baumann CL, Burkard TR, Bürckstümmer T, 
Stefanovic A, Krieger S, Bennett KL, Rülicke T, Weber F, Colinge J, Müller M, Superti-Furga G 
(2011) IFIT1 is an antiviral protein that recognizes 5'-triphosphate RNA. Nature Immunology 
12(7)624-630. 
Price GE, Ou R, Jiang H, Huang L, Moskophidis D (2000) Viral escape by selection of cytotoxic T 
cell-resistant variants in influenza-A virus pneumonia. J. Exp. Med. 191:1853–1867. 
Qi Y, Fan H, Qi X, Zhu Z, Guo X, Chen Y, Ge Y, Zhao K, Wu T, Li Y, Shan Y, Zhou M, Shi Z, 
Wang H, Cui L (2014) A novel pyrosequencing assay for the detection of neuraminidase inhibitor 
resistance-conferring mutations among clinical isolates of avian H7N9 influenza virus. Virus 
Research 179:119-124. 
Riberdy JM, Christensen JP, Branum K, Doherty PC (2000) Diminished primary and secondary 
influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice. J. Virol. 74:9762–
9765. 
Rimmelzwaan GF, Boon AC, Voeten JT, Berkhoff EG, Fouchier RA, Osterhaus AD (2004) Sequence 
variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T 
lymphocytes. Virus Res. 103:97–100. 
Rose MC, Voynow JA (2006) Respiratory tract mucin genes and mucin glycoproteins in health and 
disease. Physiol Rev 86:245-278. 
Sabbah A, Cheng TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S (2009) 
Activation of innate immune antiviral responses by Nod2. Nature Immunol 10(10)1073-80. 
Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, Renshaw M, Arpino R, Tamane A, Kandil 
A, James O, et al. (2001) Heterosubtypic immunity against human influenza A viruses, including 
recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires 
both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211:143–153. 
Schmitz N, Kurrer M, Bachmann MF, Kopf M (2005) Interleukin-1 is responsible for acute lung 
immunopathology but increases survival of respiratory Influenza virus infection. J Virol 
79(10)6441-48. 
Schnell JR, Chou JJ (2008) Structure and mechanism of the M2 proton channel of influenza A virus. 
Nature 45:591-95. 
Schotsaert M, de Filette M, Fiers , Saelens X (2009) Universal M2 ectodomain-based influenza A 
vaccines: Preclinical and clinical developments. Expert Rev. Vaccine 8:499–508. 
Schulman JL, Kilbourne ED (1963) Transmission of influenza virus infection in mice. II. Some 
factors affecting the incidence of transmitted infection. J Exp Med 125:479-488. 
Shek LP, Lee BW (2003) Epidemiology and seasonality of respiratory tract virus infections in the 
tropics. Paediatr Respir Rev 4:105-111.  
Skehel J, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza 
Hemagglutinin. Annu. Rev. Biochem 69:531-69. 
Shynia K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y (2006) Avian flu: Influenza virus 
receptors in the human airway. Nature 440:435-436. 
Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, van Kerkhove MD, 
Mounts AW, Paget WA, the GlaMOR Collaborating Teams (2013) Global mortality estimates for 
 26
the 2009 influenza pandemic from the GlaMOR Project: A modeling study. PLOS Medicine 
10(11)e1001558. 
Sridhar S, Begom S, Bermingham A, Ziegler T, Roberts KL, Barclay WS, Openshaw P, Lalvani A 
(2012) Predominance of heterosubtypic IFN-gamma-only-secreting effector memory T cells in 
pandemic H1N1 naive adults. Eur. J. Immunol. 2012:doi:10.1002/eji.201242504. 
Sriwilaijaroen N & Suzuki Y (2012) Molecular basis of the structure and function of H1 
hemagglutinin of influenza virus. Proc Jpn Acad Ser B 88:226-249. 
Strutt TM, McKinstry KK, Dibble JP, Winchell C, Kuang Y, Curtis JD, Huston G, Dutton RW, Swain 
SL (2010) Memory CD4+ T cells induce innate responses independently of pathogen. Nat. Med. 
16:558–564. 
Su CTT, Schönbach C, Kwoh CK (2014) Molecuar docking analysis of 2009-H1N1 and 2004-H5N1 
influenza virus HLA-B*4405-restricted HA epitope candidates: implications fot TCR cross-
recognition and vaccine development. BMC Bioinformatics 14(suppl 2):S21.  
Sun X, Jayaraman A, Maniprasad P, Raman R, Houser KV, Pappas C, Zeng H, Sasisekharan R, Katz 
JM, Tumpey TM (2013) N-linked glycosylation of the hemagglutinin protein influences virulence 
and antigenicity of the 1918 pandemic and seasonal H1N1 influenza A viruses. J Virol 
87(15):8756-66.  
Tan SL, Katze MC (1998) Using genetic means to dissect homologous and heterologou protein-
protein interactions of PKR, the Interferon-induced protein kinase. Methods 15(3)207-223. 
Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, Farber DL (2011) Cutting edge: Tissue-
retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. 
Immunol. 187:5510–5514. 
Thakaramaran K, Raman R, Viswanathan K, Stebbins NW, Jayaraman A, Krishnan A, Sasisekharan 
V, Sasisekharan R (2012) Structural determinants for naturally evolving H5N1 hemagglutinin to 
switch its receptor specificity. Cell 153:1475-1485. 
Thakaramaran K, Jayaraman K, Raman R, Viswanathan K, Stebbins NW, Johnson D, Shriver Z, 
Sasisekharan V, Sasisekharan R (2013) Glycan receptor binding of the influenza A virus H7N9 
hemagglutinin. Cell 153:1486-1493. 
The 1000 Genomes Consortium (2010) A map of human genome variation from population-scale 
sequencing. Nature 467:1061-73. 
Throsby M, van den Brink E, Jongeneelen M, Poon LLM, Alard P, Cornelissen L, Bakker A, Cox F, 
van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, 
Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against 
H5N1 and H1N1 recovered from human IgM+ Memory B cells. PloS ONE 3(12)e3492. 
Tompkins S M, Zhao Z S, Lo C Y, Misplon J A, Liu T, Ye Z, Hogan R J, Wu Z, Benton K A, 
Tumpey T M, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, 
including subtype H5N1. Emerg. Infect. Dis. 13:426–435. 
Tria F, Pompei S, Loreto V (2013) Dynamically correlated mutations drive human Influenza A 
evolution. Nature Scient. Rep. 3:2705. 
Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solórzano A, Swayne DE, Cox NJ, Katz JM, 
Taubenberger JK, Palese P, García-Sastre A (2005) Characterization of the reconstructed 1918 
Spanish influenza pandemic virus. Science 310:77-80. 
Uipraserktul M, Puthavathana P, Sangsiriwut K, Pooruk P, Srisook K, Peiris M, Nicholls JM, 
Chokephaibulkit K, Vanprapar N, Auewarakul P (2005) Influenza A H5N1 replication sites in 
humans. Emer Infect Dis 11(7)1036-1041. 
van den Brand JMA, Stittelaar KJ, van Amerongen G, Rimmelzwaan GF, Simon J, de Wit E, Munster 
V, Bestebroer T, Fouchier RAM, Kuiken T, Osterhaus ADM (2010) Severity of pneumonia due to 
new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and 
highly pathogenic influenza H5N1 virus. J Infec Dis 201:993-999. 
van Domselaar R, Bovenschen N (2011) Cell death-independent functions of granzymes: Hit viruses 
where it hurts. Rev. Med. Virol. 21:301–314. 
van Gisbergen KP, Klarenbeek PL, Kragten NA, Unger PP, Nieuwenhuis MB, Wensveen FM, ten 
Brinke A, Tak PP, Eldering E, Nolte MA, et al. (2011) The costimulatory molecule CD27 
maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral 
variants. Immunity 35:97–108. 
 27
van Riel D, Leijten LM, van der Eerden M, Hoogsteden HC, Boven LA, Lambrecht BN, Osterhaus 
AD, Kuiken T (2011) Highly pathogenic avian influenza virus H5N1 infects alveolar macrophages 
without virus production or excessive TNF-alpha induction. PLoS Pathog. 7(6)e1002099. 
Varki A, Gagneux P (2012) Multifarious roles of sialic acids in immunity. Ann. N. Y. Acad. Sci. 
1253:16-36. 
Viboud C, Alonso WJ, Simonsen L (2006) Influenza in tropical regions. PLoS Med 3:e89; 
doi:10.1371/journal.pmed.0030089.  
Voeten JT, Groen J, van Alphen D, Claas EC, de Groot R, Osterhaus AD, Rimmelzwaan GF (1998) 
Use of recombinant nucleoproteins in enzyme-linked immunosorbent assays for detection of virus-
specific immunoglobulin A (IgA) and IgG antibodies in influenza virus A- or B-infected patients. 
J. Clin. Microbiol. 36:3527–3531. 
Voeten JT, Bestebroer TM, Nieuwkoop NJ, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2000) 
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by 
cytotoxic T lymphocytes. J. Virol. 74:6800–6807. 
von Itzstein M (2007) The war against influenza: discovery and development of sialidase inhibitors. 
Nat Rev Drug Disc 6:967-974. 
Voynow JA, Selby DM, Rose MC (1998) Mucin gene expression (MUC1, MUC2, and MUC5/5AC) 
in nasal epithelial cells of cystic friborsis, allergic rhinitis and normal individuals. Lung 176:345-
354.  
Waffarn EE, Baumgarth N (2011) Protective B cell responses to flu – No fluke! J. Immunol. 
186:3823–3829. 
Wagner R, Matrosovich M, Klenk HD (2002) Functional balance between haemagglutinin and 
neuraminidase in influenza virus infections. Rev Med Virol 12:159-166. 
Wallace RG and Fitch WM (2008) Influenza A H5N1 immigration is filtered out at some international borders. 
PLoS One 3:e1697. 
Wang Y, Zhou L, Shi H, Xu H, Yao H, Xi X G, Toyoda T, Wang X, Wang T (2009) Monoclonal 
antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of 
influenza A viruses in MDCK cells. Biochem. Biophys. Res. Comm. 385:118–122. 
WHO – World Health Organization (http://www.who.int/en/ - last accessed on May 9th, 2014). 
Wijburg OLC, Heemskerk MHM, Boog CJP, van Rooijen N (1997) Role of spleen macrophages in 
innate and acquired immune responses against mouse hepatitis virus strain A59. Immunology 
92:252-58.  
Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, 
Oxford J, Nicholas B, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with 
disease protection against influenza challenge in humans. Nat. Med. 18 274–280. 
Worobey M, Guan-Zhu H, Rambaut A (2014) Genesis and pathogenesis of the 1918 pandemic H1N1 
influenza A virus. Proc. Nat. Acad. Sci. 111 8107-8112. 
Yang ML, Chen YH, Wang SW, Huang YJ, Leu CH, Yeh NC, Chu CY, Lin CC, Shieh GS, Chen YL, 
Wang JR, Wang CH, Wu CL, Shiau AL (2011) Galectin-1 binds to influenza virus and 
ameliorates influenza virus pathogenesis. J. Virol. 85(19)10010-20.  
Yang Z, Huffman FL (2013) Nutrition in pregnancy and early childhood and associations with obesity 
in developing countries. Maternal and Child Nutrition 9 (Suppl. 1) 105–119. 
Yu X, Tsibane T, McGraw P A, House F S, Keefer C J, Hicar M D, Tumpey, T M, Pappas C, Perrone 
L A, Martinez O, et al. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza 
pandemic survivors. Nature 455 532–536. 
Zhou J, To KKW, Dong H, Cheng ZS, Lau CCY, Poon VKM, Fan YH, Song YQ, Tse H, Chan KH, 
Zheng BJ, Zhao GP, Yuen KY (2012) A functional variation in CD55 gene increases the disease 
severity of pandemic A(H1N1)2009 influenza infection. J. Infect. Dis.206(4)495-503. 
Zhu J, Paul WE (2010a) Heterogeneity and plasticity of T helper cells. Cell Res. 20:4–12. 
Zhu J, Paul WE (2010b) Peripheral CD4+ T-cell differentiation regulated by networks of cytokines 
and transcription factors. Immunol. Rev. 238:247–262. 
Zimmermann C, Prevost-Blondel A, Blaser C, Pircher H (1999) Kinetics of the response of naive and 
memory CD8 T cells to antigen: Similarities and differences. Eur. J. Immunol. 29:284–290. 
 
